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Ewing sarcoma is a highly aggressive pediatric malignancy that is characterized 
by a chromosomal translocation-derived fusion protein, Ewing sarcoma (EWS)/ Friend 
leukemia insertion (FLI), EWS/FLI. EWS/FLI is an aberrant transcription factor and its 
downstream targets contribute to oncogenic transformation in Ewing sarcoma. However, 
the mechanisms of transcriptional regulation by EWS/FLI and the full complement of 
direct targets of EWS/FLI were previously unknown. The work documented in this 
dissertation describes a novel basis for EWS/FLI function in gene activation, and also 
uncovers a mechanism by which EWS/FLI directly represses a subset of critical targets 
genes in Ewing sarcoma.  
Through the identification of direct in vivo targets of EWS/FLI, we made an 
unexpected discovery that EWS/FLI activates some of its critical target genes, including 
NR0B1 and GSTM4, by binding to microsatellite repeats. These findings suggest a new 
paradigm for cancer-relevant gene regulation by EWS/FLI, and perhaps other ETS family 
members. 
In addition to the microsatellite repeats, EWS/FLI regulates some of its target 
genes through the canonical high-affinity consensus E-26 oncogene (ETS) site. We 
focused on one such target gene, GLI1, and uncovered a novel role for GLI1 and its 
downstream target, KRT17, in coordinating two cancer-relevant functions: oncogenic 
transformation and cellular adhesion in Ewing sarcoma.  
  iv   
The functional relationship between wild-type EWS and the EWS/FLI fusion 
protein in Ewing sarcoma was largely unknown. Through global transcription profiling 
and mechanistic studies we demonstrated that EWS and EWS/FLI coregulate a subset of 
genes in Ewing sarcoma and that EWS functions as a cofactor of the REST transcription 
factor to repress neuronal differentiation genes. These data suggest that EWS, and 
consequently EWS/FLI, have transcriptional repressive roles in Ewing sarcoma. 
We next focused on identifying and characterizing the mechanism underlying 
EWS/FLI-mediated direct transcriptional repression. We demonstrated that EWS/FLI 
interacts with the nucleosome remodeling and histone deacetylase (NuRD) corepressor 
complex to repress critical tumor suppressor genes in Ewing sarcoma. These data identify 
inhibitors of the NuRD complex components as potentially effective therapeutic agents 
for the treatment of Ewing sarcoma.  
Taken together, the work presented in this dissertation advances our molecular 
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CHAPTER 1 
INTRODUCTION 
Ewing sarcoma: Disease and molecular genetics 
Ewing sarcoma accounts for one-third of all primary bone tumors in children and 
young adults and is the second most common bone-associated malignancy in the pediatric 
population with a peak incidence at about 15 years of age (1, 2). There are approximately 
250 newly diagnosed Ewing sarcoma cases in the United States per year (SEER). It is a 
highly undifferentiated tumor and histologically has a characteristic small-round blue cell 
appearance as depicted in Figure 1.1. Ewing sarcoma most frequently arises in the bone, 
but <10% of tumors arise in soft tissues (3). It is a highly aggressive disease and 
approximately 25% of patients present with overt metastasis at the time of clinical 
diagnosis (4). In addition, patients with clinically undetectable metastasis likely have 
micrometastatic disease, because in the absence of systemic chemotherapy most patients 
relapse with distant metastatic disease (5, 6). The common sites of metastasis include 
lung, bone and bone-marrow. The propensity to spread leads to poor prognosis for Ewing 
sarcoma patients with the five year survival rate for localized disease being ~70%, which 
drops to ~10% for metastatic disease (7).  
Although Ewing sarcoma commonly presents as a bone-associated neoplasm, the 
cell-of-origin of this tumor is still an area of active debate, since it was first described by
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 James Ewing in 1921 (8, 9). Several lines of evidence support a neural crest cell of 
origin for Ewing sarcoma (10). Early studies showed that Ewing sarcomas express cell 
surface antigens associated with the neuroectodermal lineage (11-13). Later, a gene 
expression profiling study found that genes expressed in neuronal tissues or during 
neuronal differentiation are abundantly expressed in Ewing sarcomas (14). Furthermore, 
ectopic expression of the fusion protein encoded by the Ewing sarcoma gene (EWS) and 
Friend leukemia insertion gene (FLI), EWS/FLI, in non-Ewing cells including 
rhabdomyosarcoma, neuroblastoma or human foreskin fibroblast cell lines resulted in an 
upregulation of genes critical for neural crest development (15-17). Although, these data 
implicated a role for EWS/FLI in driving the neural phenotype of Ewing sarcoma cells, 
not much was known about the mechanisms that contributed to the neuronal phenotype 
and, importantly, the critical factors that prevented full neuronal differentiation of Ewing 
sarcomas. The work highlighted in Chapter 6 of this dissertation provides new insights in 
this direction. 
In addition to neural crest cells, there is a growing body of recent evidence 
suggesting that mesenchymal stem cells (MSCs) are the likely progenitor cells of Ewing 
sarcoma (18-20). Interestingly, it has also been recently suggested that the two proposed 
cells of origin, neural crest and MSCs, may not be mutually exclusive (21). Since neural-
derived MSCs are present in the bone-marrow (22) and, conversely, neural crest stem 
cells contain some mesenchymal lineage plasticity (23), it is possible that Ewing 




In the mid-1980s it was discovered that 85% of Ewing sarcomas harbored a 
tumor-specific chromosomal translocation, t(11;22)(q22;q12), generating a fusion protein 
EWS/FLI, from the in-frame fusion of the amino-terminus of EWS (encoded by EWSR1), 
a member of the TET (TLS/EWS/TAF15) family of RNA-binding proteins, and the 
carboxyl-terminus of FLI (encoded by FLI1), a member of the ETS family of 
transcription factors, as depicted in Figure 1.2 (24, 25). The reciprocal FLI/EWS 
translocation is not expressed in Ewing sarcoma tumors and the reciprocal translocated 
chromosome is sometimes lost from these tumors (26, 27). In addition to the gain of 
function of EWS/FLI, the t(11;22)(q24;q12) translocation causes loss of one allele of the 
wild-type EWSR1 and FLI1 genes (26). The untranslocated wild-type FLI allele is not 
expressed in Ewing sarcomas (27). Therefore, in addition to generation of EWS/FLI the 
other major consequence of the translocation is the haplo-insufficiency of EWS. Not 
much was known about the functional consequence of the halo-insufficiency of EWS on 
Ewing sarcoma oncogenesis. The work described in Chapter 6 of this dissertation has 
addressed this question. Some insight into the functioning of the EWS/FLI fusion protein 
also can be gained from knowledge about the wild-type EWS and FLI proteins.  
 
Wild-type EWS 
EWS is encoded by the EWSR1 gene (Ewing’s sarcoma rearrangement domain 1), 
first identified in the context of Ewing sarcoma (25). EWS is a ubiquitously expressed 
nuclear protein (25, 28). The amino-terminus of EWS included in EWS/FLI is highly 
unstructured, consists of a repetitive primary sequence with several copies of a 
degenerate hexapeptide repeat motif (SYGQQS) that resembles the carboxyl-terminal 
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domain of RNA polymerase II (25), suggesting a potential role for EWS in transcriptional 
activation. The N-terminal domain of EWS has been shown to interact with the basal 
transcription factor TFIID, with certain subunits of RNA polymerase II and p300/CBP, 
providing additional support for the transcriptional activating potential of EWS (29-32). 
The EWS/FLI fusion protein does not form a stable complex with RNA polymerase II 
(30) but does interact with the RNA polymerase II subunit RPB7 (29), highlighting a 
likely conservation in function between wild-type EWS and the EWS/FLI fusion protein 
in transcriptional activation. 
The unstructured nature of the N-terminal EWS domain potentially enables its 
interaction with several proteins subsequently leading to the pathogenic transcriptional 
activities of EWS and EWS/FLI (33). As an example, it was demonstrated that wild-type 
EWS could interact with its oncogenic derivative EWS/FLI to induce mitotic defects and 
genomic instability and, in doing so, contribute to the transformed phenotype of Ewing 
sarcoma (34). In support of this are data highlighting a developmental role for EWS in 
genome surveillance and DNA repair (35, 36). The carboxyl-terminus of EWS, which is 
not retained in EWS/FLI, is thought to interact with the serine-arginine family of RNA 
splicing factors as evidenced by the presence of 3 RGG-rich regions (37) (Figure 1.2), 
suggesting a potential role for wild-type EWS in RNA processing/splicing or export (28). 
In addition to the possible roles for EWS in transcriptional activation, DNA-
repair, and RNA processing, a recent study demonstrated that EWS could repress the 
expression of a reporter gene it was tethered to, by inhibition of posttranscriptional gene 
expression (38). Upon DNA-damage signals, the EWS family member TLS has been 
shown to be recruited to the CCND1 gene promoter by a tethered ncRNA to inhibit the 
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histone acetyl transferase activity of CBP/p300, leading to transcriptional repression of 
the CCND1 gene (39). These studies indicate that TET family proteins including EWS 
may also function in a repressive capacity. Notably, without evidence that EWS binds to 
double stranded DNA in vivo, EWS is more likely to act as a transcriptional cofactor than 
as a transcription factor.  
Since the EWS/FLI fusion protein has been the main focus of study in the field, 
very little was known about the role of wild-type EWS in Ewing sarcoma, leaving many 
unanswered questions: Does EWS function as a cofactor to affect transcription of target 
genes? What are EWS regulated genes, if any, in Ewing sarcoma and does the EWS 
transcriptional profile contribute significantly to the EWS/FLI transcriptional profile? 
Does wild-type EWS have a role in oncogenic transformation? The work presented in 
Chapter 6 provides new insights into the role of wild-type EWS in Ewing sarcoma. 
 
Wild-type FLI 
The other portion of the EWS/FLI fusion is contributed by FLI1, which encodes 
the protein FLI. FLI is a member of the ETS family of transcription factors (40). There 
are 27 known ETS family members in humans, which may be grouped on the basis of 
similarities in their ETS domains (41). ETS family members play a prominent role in 
cancer development because genes encoding ETS factors are often involved in 
chromosomal translocations that generate oncogenic protein derivatives (41). FLI 
localizes to the nucleus and functions primarily in megakaryocyte, vascular, and neural 
crest development (42-44). FLI can also function as an oncogene. The murine Fli locus 
was first identified as the predominant Friend murine leukemia virus (F-MuLV) insertion 
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site, which causes upregulation of the Fli gene, and the development of erythroleukemia 
(45, 46). Exogenous expression of FLI in transforming models like NIH3T3 immortalized 
murine fibroblasts, however, does not result in oncogenic transformation (47). Therefore, 
its transforming ability may be limited to the hematopoietic lineage. The amino-terminus 
of FLI contains a pointed (PNT) domain, which is involved in protein-protein 
interactions, and functions as a weak transcriptional activation or repression domain (48). 
However, the PNT domain of FLI is lost in the EWS/FLI fusion protein (refer to Figure 
1.2). The carboxyl-terminus of FLI contains a highly conserved ~85 amino acid DNA 
binding domain (ETS domain) that is both necessary and sufficient for site-specific DNA 
binding (48). EWS/FLI retains this C-terminal ETS domain of FLI (refer to Figure 1.2). 
 
TET/ETS and non-TET/ETS fusions 
EWS/FLI is expressed in ~85% of Ewing sarcoma tumors. In the remaining 10% 
of cases, translocations resulting in the fusion of EWS [and rarely a related 
TLS/ETS/TAF15 (TET) family protein] with other ETS family members occur. Thus, 
EWS/ERG, EWS/ETV1, EWS/ETV4 and EWS/FEV have all been described in Ewing 
sarcoma, and are all thought to mimic the function of EWS/FLI (25, 49-52). These 
findings solidified the importance of TET/ETS fusions in the pathogenesis of Ewing 
sarcoma and have since been used as diagnostic markers for the disease (53). 
EWS fusions with non-ETS transcription factor family members have been 
described in a variety of sarcomas that are distinct from Ewing sarcoma. However, in 
recent years, a small but increasing number of rare non-TET/ETS rearrangements have 
been identified in sarcomas called “Ewing’s-like tumors” that anatomically and 
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histologically resemble certain features of Ewing sarcoma (refer to Chapter 2). These 
findings have complicated both molecular diagnostics as well as the concept that Ewing 
sarcoma is strictly a TET/ETS fusion driven malignancy. However, due to lack of a 
molecular understanding of the non-TET/ETS fusions and their mechanisms of action it 
is difficult to conclude that these fusions drive the same disease as the TET/ETS fusions.  
 
EWS/FLI functions as a fusion oncoprotein 
EWS/ETS proteins are characterized as oncoproteins in Ewing sarcoma. 
However, introduction of EWS/ETS proteins into different cellular models result in 
diverse outcomes ranging from the induction of cell cycle arrest or apoptosis to 
transformation and tumorigenicity, and from blocking differentiation to trans-
differentiation (9). Thus, the phenotype driven by EWS/ETS proteins depends on the 
cellular context. Ectopic expression of EWS/FLI is not sufficient to transform many 
primary cell types, including primary human fibroblasts, primary mouse fibroblasts and 
immortalized rat fibroblasts (Rat1 cells), and instead results in cell death or growth arrest 
(17, 54). Expression of EWS/FLI in more primitive cells including primary neural crest 
progenitor cells (Ncm1) or tumor cell lines like rhabdomyosarcoma (CTR) cells, results 
in differentiation defects (9). These studies highlight the importance of a permissive 
cellular background that is necessary for EWS/FLI function and subsequent cellular 
transformation.  
Ectopic expression of EWS/FLI causes oncogenic transformation of NIH3T3 cells 
(47, 55, 56), indicating that in this cell type perhaps there are unknown cooperating 
aberrancies or pathways that permit cellular transformation upon EWS/FLI 
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overexpression. Subsequent studies within a native Ewing sarcoma cellular context have 
demonstrated that stable knockdown of EWS/FLI in multiple patient-derived Ewing 
sarcoma cell lines resulted in loss of oncogenic transformation, assessed by anchorage-
independent growth in soft agar in vitro and xenograft tumor growth in vivo in 
immunodeficient mice (27, 57). Furthermore, reexpression of an RNAi-resistant 
EWS/FLI cDNA resulted in restoration of the transformed phenotype (58). Therefore, 
EWS/FLI or other EWS/ETS fusions are presumably the initiating oncogenic events, and 
their ongoing expression is required for the transformed phenotype of Ewing sarcoma. 
Site directed mutagenesis within the DNA binding domain of the FLI portion, or 
large deletion mutations within the EWS portion of EWS/FLI, result in a complete loss of 
biologic activity of the EWS/FLI fusion protein (refer to Chapter 7). Therefore, both the 
EWS and FLI portions of EWS/FLI, and the DNA binding ability of EWS/FLI are 
essential for oncogenic transformation (47, 55, 56). The N-terminal EWS domain confers 
a strong transcription activation domain when fused to heterologous DNA-binding 
domains of other transcription factors (55). These data suggests that the N-terminal EWS 
domain that is retained in the EWS/FLI fusion protein functions predominantly as a 
strong transcriptional activation domain.  
Although EWS/FLI binds DNA with the same specificity as wild-type FLI, it acts 
as a more potent transcriptional activator, owing to the replacement of the weak 
transcriptional activation domain (from wild-type FLI) by the strong transcriptional 
activation domain of EWS (47, 56). This concept was supported by a study that found 
that replacement of the EWS domain in EWS/FLI with other strong transcriptional 
activation domains could rescue oncogenic transformation in NIH3T3 cells, whereas 
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replacement with a weak transcriptional activation domain could not (55) (Figure 1.3). 
These data suggest that EWS/FLI-mediated transcriptional activation drives oncogenic 
transformation. However, later data from patient-derived Ewing sarcoma cell lines and 
primary tumors suggested that transcription repression by EWS/FLI is also necessary for 
oncogenic transformation (27, 57, 59). In fact, as detailed later in Chapter 7, it is the 
combined effect of EWS/FLI-mediated gene activation and gene repression that causes 
full oncogenic transformation of Ewing sarcoma cells. Furthermore, EWS/FLI, but not 
wild-type FLI, transforms NIH3T3 cells, highlighting a gain-of-function of the fusion 
protein (47). Taken together, these findings indicate that EWS/FLI acts as an aberrant 
transcription factor, inappropriately regulating the expression of specific repertoires of 
target genes, thereby orchestrating development of Ewing sarcoma. 
 
DNA binding and regulation by ETS proteins 
EWS/FLI retains the ETS-type DNA binding domain of FLI (Figure 1.2). ETS 
proteins have a characteristic winged helix-loop-helix DNA-binding domain (60, 61). 
Most ETS family members bind as monomers to sequences of DNA that contain a 
GGAA (or rarely a GGAT) “core” motif (40, 41, 48); the flanking nucleotides modulate 
the affinity and specificity of the interaction (62). In vitro binding site selection 
approaches identified a high-affinity consensus ETS binding sequence, ACCGGAAGTG, 
which acts as a functional binding site for wild-type FLI and for most ETS family 
members (63). EWS/FLI also binds to this site with high affinity (63).  
Genome-wide localization approaches have identified two distinct classes of ETS 
binding sites in vivo:  high-affinity (redundant sites), and divergent (specific sites) (64). 
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The high affinity sites identified were bound by multiple ETS family members in vivo, 
indicating that although there are preferences, the DNA-binding specificity for ETS 
factors is not stringent. In contrast, the divergent sites consist of partial ETS binding sites 
overlapping with, or in immediate proximity to, partial binding sites for non-ETS family 
members. Such binding sites could potentiate gene regulation by cooperative interactions 
between an ETS protein and another transcription factor. Divergent ETS binding sites 
have been identified in a number of ETS target genes (65) and DNA binding of ETS 
proteins is modulated by their interactions with other transcription factors (66, 67). 
Interestingly, ETS family proteins that participate in Ewing sarcoma, including FLI1, 
ERG, and ETV1, can cooperatively bind DNA with AP1 (Fos-Jun) proteins (68). 
Importantly, a truncated mutant form of EWS/FLI that failed to cooperatively bind DNA 
with AP1 proteins failed to transform NIH3T3 cells (68), highlighting the significance of 
cooperative DNA binding and transcriptional regulation from weak divergent ETS sites 
in the pathogenesis of Ewing sarcoma.  
The presence of the FLI DNA-binding domain in the EWS/FLI fusion protein 
suggests that EWS/FLI likely binds similar DNA sequences and targets similar genomic 
sites as does the wild-type FLI protein. However, little was known about the nature of the 
binding motifs for EWS/FLI in Ewing sarcoma. Work detailed in Chapter 3 of this 
dissertation identified, for the first time, in vivo binding elements of EWS/FLI in Ewing 






 EWS/FLI target genes in Ewing sarcoma 
While the identification of EWS/FLI was an important step forward, progress in 
understanding the pathogenesis of Ewing sarcoma has been precluded by the lack of 
knowledge of the cell-of-origin, and therefore the inability to generate genetic models of 
the disease (9, 69). EWS/FLI functions as an aberrant transcription factor in Ewing 
sarcoma which implies that EWS/FLI regulated genes are important for oncogenesis. 
Early studies made use of NIH3T3 cells, but few of the EWS/FLI “targets” identified in 
this cell type have been validated as being involved in bona fide Ewing sarcoma (70-73). 
The biggest pitfall of these studies was the use of a heterologous cell type requiring the 
nonphysiologic overexpression of EWS/FLI and a lack of understanding of the 
background genetic aberrancies in NIH3T3 cells that aid EWS/FLI-mediated 
transformation. Indeed, our own work has demonstrated that EWS/FLI expression in 
NIH3T3 cells induces a gene expression pattern that is quite different from the pattern 
induced in Ewing sarcoma (58, 74), suggesting that EWS-FLI1 may trigger a generic 
ETS-mediated gene expression pattern and transformation process in NIH3T3 cells, 
rather than a Ewing sarcoma-specific process. These data underscored the importance of 
studying EWS/FLI and the target genes it dysregulates within a native cellular context.  
To identify EWS/FLI targets within a native cellular context, our lab developed a 
strategy to knockdown endogenous EWS/FLI expression in patient-derived Ewing 
sarcoma cell lines using a retroviral-based stable shRNA approach, without drastically 
affecting the normal growth rate of cells in tissue culture, followed by gene expression 
profiling (27). The specificity of the RNAi construct against EWS/FLI was validated by a 
“rescue” approach re-expressing an RNAi-resistant EWS/FLI cDNA (58). Importantly, as 
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highlighted previously, stable knockdown of EWS/FLI resulted in loss of oncogenic 
transformation assessed by in vitro and in vivo assays and rescue with the RNAi-resistant 
EWS/FLI cDNA restored the transformed phenotype. Therefore, target genes identified 
using this approach would potentially identify critical downstream mediators of EWS/FLI 
function in driving Ewing sarcoma oncogenesis. 
Using this approach we and others have identified several thousands of genes 
regulated by EWS/FLI (27, 57, 59, 75). Importantly, target genes identified within the 
native cellular context have since been validated as bone fide targets, important for 
various aspects of Ewing sarcoma development. Furthermore, identification of the 
EWS/FLI transcriptome provided us with target genes that could then be used as tools to 
understand the mechanisms of regulation by EWS/FLI and to identify EWS/FLI response 
elements. Specifically, NR0B1 and GSTM4, among others, were identified as key 
upregulated EWS/FLI target genes absolutely essential for oncogenic transformation 
(27). As detailed in Chapters 3 and 4, we utilized the NR0B1 and GSTM4 promoters as 
candidates to identify and characterize EWS/FLI response elements in Ewing sarcoma. 
In contrast to the NIH3T3 transcription profile, the most striking observation from 
the EWS/FLI transcription profile generated in Ewing sarcoma cells was that there were 
several fold more downregulated target genes than there were EWS/FLI upregulated 
targets (76). This was intriguing given that EWS/FLI was predominantly characterized as 
a transcriptional activator, with the exception of a few reports that suggested that target 
gene repression by EWS/FLI may be important to the tumorigenic phenotype (47, 55, 75, 
77). The repressed gene signature for EWS/FLI was also confirmed by a more recent 
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RNA-sequencing experiment (refer to Chapter 6). However, the exact mechanism of 
EWS/FLI-mediated repression in Ewing sarcoma remained unanswered.  
Transcription profiling experiments have identified several thousands of 
EWS/FLI targets including several critical effectors of oncogenic transformation, but the 
big unanswered questions in the field were: does the EWS/FLI transcription profile 
contain direct targets in addition to indirect targets? How does the fusion oncoprotein 
regulate its critical target genes? Therefore, identification of “direct” EWS/FLI targets 
(defined by EWS/FLI binding to the promoter and/or enhancer elements of target genes) 
and a detailed characterization of direct binding sites for EWS/FLI at target gene 
promoters were necessary to better understand the underlying mechanisms of regulation. 
Overlapping direct EWS/FLI targets with EWS/FLI up or downregulated genes from the 
transcription profiles would then identify a “core” set of target genes for further focused 
mechanistic studies. Work detailed in Chapters 3, 4 and 7 have utilized this approach. 
 
Transcriptional activation in Ewing sarcoma 
Among the genes activated by EWS/FLI, our lab has previously demonstrated that 
NKX2.2 and NR0B1 are critical upregulated targets necessary for EWS/FLI mediated 
oncogenic transformation (27, 57). Interestingly, another EWS/FLI upregulated gene 
initially identified in our microarray-based transcriptional profiling studies was GLI1 
(Glioma associated oncogene homolog 1) (27). GLI1 is a zinc-finger transcription factor 
and is the principal effector of the Hedgehog signaling pathway (78). Hedgehog signaling 
is of critical importance during development for proper cellular differentiation, tissue 
patterning and stem cell maintenance (78, 79). This signaling pathway is well recognized 
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to contribute to the development and progression of several cancers (80). The canonical 
pathway for GLI activation requires ligand-dependent inhibition of the receptor Patched 
(PTCH), which releases inhibition of the signal transducer Smoothened (SMO), allowing 
for GLI-dependent transcription of genes that mediate cell proliferation and survival.  
We demonstrated that GLI1 was transcriptionally activated in a noncanonical 
fashion in Ewing sarcoma cells, independent of upstream hedgehog pathway components, 
by direct EWS/FLI binding to a high-affinity ETS consensus site in the GLI1 promoter. 
Furthermore, we identified a role for GLI1 in EWS/FLI-mediated oncogenic 
transformation. While we were working on further characterizing the role of GLI1, 
several papers were published that highlighted the importance of GLI1 in Ewing sarcoma 
development. These studies independently validated our findings that EWS/FLI directly 
activated transcription from the GLI1 promoter (81), and that loss-of-function approaches 
and pharmacological inhibition of GLI1 significantly decreased oncogenic transformation 
(81-84). However, the mechanism underlying GLI1-mediated oncogenesis and the 
critical transcriptional network of genes regulated by GLI1 to achieve this function 
remained unknown. Work detailed in Chapter 5 of this dissertation addresses these 
critical questions and provides a mechanistic understanding of GLI1-mediated oncogenic 
transformation in Ewing sarcoma. 
 
Transcriptional repression in Ewing sarcoma  
Transcriptional repression is central to the pathogenesis of hematologic 
malignancies, including acute myelogenous leukemia (AML) and acute lymphoblastic 
leukemia (ALL). Acute promyelocytic leukemia (APML) is associated with the 
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chromosomal translocation, t(15;17)(q24;q12) encoding the PML/RARα fusion product. 
The PML/RARα fusion acts as a transcriptional repressor, due to its interaction with 
Histone Deacetylases (HDACs) which leads to repression of the retinoic acid response 
genes (85-87). In contrast, chromosomal fusion-driven solid tumor development has 
largely been attributed to transcriptional activation. For example, the PAX3/FKRH fusion 
in alveolar rhabdomysosarcoma, TLS/CHOP in myxoid liposarcoma and the EWS/ATF1 
fusion in clear cell sarcoma have been characterized predominantly as transcriptional 
activators (88-90).  
Similarly, evidence from early studies in heterologous cell systems had suggested 
a role for EWS/FLI in transcriptional activation (47, 55). However, as previously 
highlighted, gene expression profiling studies in Ewing sarcoma cells displayed a 
predominant signature of EWS/FLI repressed genes (27). This repression may be 
attributed, in part, to the upregulation of transcriptional repressors by EWS/FLI. This 
might suggest an indirect repression model, which would still support the concept that 
EWS/FLI is predominantly a transcriptional activator.  
In support of the indirect repression model, previous studies have shown that 
EWS/FLI activates the expression of Enhancer of Zeste Homolog 2 (EZH2), the 
enzymatic subunit of the polycomb PRC2 repressor complex, which methylates histone 
H3 Lys27, and thereby mediates gene repression. Silencing of EZH2 in Ewing sarcoma 
cells decreased tumor growth and metastasis, and resulted in a generalized loss of 
methylation on H3 Lys27 and an increase in H3 acetylation, leading to gene activation 
(91). Previous work from our lab has identified other EWS/FLI upregulated proteins like 
NKX2.2 and NR0B1 that function predominantly as transcriptional repressors in Ewing 
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sarcoma and contribute to a small but significant proportion of the EWS/FLI repressed 
gene signature (76, 92). NKX2.2 mediates repression in Ewing sarcoma through 
recruitment of HDAC activity. Consequently, treatment with the HDAC inhibitor 
vorinostat resulted in a reversal of the NKX2.2-mediated repression of target genes and 
consequently blocked oncogenic transformation (76). These studies highlight the 
importance of gene repression in Ewing sarcoma oncogenesis and, in addition, suggest a 
critical role for HDACs and other epigenetic regulator proteins as effectors of 
transcriptional repression in Ewing sarcoma.  
 
Histone deacetylases (HDACs) 
Gene repression is largely achieved by the combinatorial action of various 
enzymatic complexes, known as corepressor complexes, which are recruited to DNA by 
transcription factors and act by modifying histone tails and thereby changing the 
chromatin architecture at target gene promoters. One of the most important processes that 
mediates transcriptional repression is deacetylation of histone tails facilitated by HDAC 
proteins (93). In vertebrates, HDACs contain 11 members (HDAC1-HDAC11), which 
are divided into three classes: class I (HDAC1-3, HDAC8), class II (HDAC4-HDAC7, 
HDAC9-10) and class IV (HDAC11). Class III HDACs are the sirtuin family of NAD+-
dependent deacetylases (94-97). Acetylation of histone tails is associated with relaxation 
of the chromatin structure and increased transcriptional activity. At repressed gene 
promoters, removal of acetyl groups from histone tails results in a condensed DNA 
structure, preventing gene expression. Class I HDACs are catalytic subunits of 
multiprotein corepressor complexes that mediate transcriptional repression. HDAC1 and 
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HDAC2 are components of the SIN3A corepressor complex (98, 99), the RE1 silencing 
transcription factor complex (REST) (100-102) and the Nucleosome remodeling and 
histone deacetylase complex (NuRD) (103-106). HDAC3 is recruited to promoters by 
association with the NCoR/SMRT repressor complex (93). 
 
NuRD (Nucleosome remodeling and histone deacetylase) complex 
The nucleosome remodeling and histone deacetylase complex (NuRD) is an 
interesting corepressor complex because it combines several enzymatic activities in one 
large multiprotein complex. The NuRD complex, also known as Mi-2, is about 2MDa in 
size and is comprised of HDAC1 and HDAC2, and two histone binding proteins, 
RbAp46 and RbAp48 (107). In addition to HDACs, the NuRD complex also consists of 
an ATP-dependent nucleosome remodeling activity due to the presence of the Mi-2/CHD 
family of proteins which have a chromodomain, a DNA helicase/ATPase domain of the 
SWI/SNF family, and a PHD domain (107). The NuRD complex also contains MTA 
family proteins, MTA1 or MTA2, first identified as metastasis associated proteins in 
carcinomas (108). The MTA proteins have a zinc finger and a SANT domain (both are 
domains that bind DNA). Additionally, the NuRD complex contains the methyl CpG-
binding domain protein, MBD3 (109) as well as a lysine-specific histone demethylase, 
LSD1 (110). It is, however, important to note that some of the components are not 
exclusive to the NuRD complex and different combinations of these complex members 
exist in other corepressor protein complexes. Like most classes of chromatin remodeling 
complexes, the NuRD complex has important roles in transcription, chromatin assembly, 
cell cycle progression and genomic stability (111). The NuRD complex is evolutionarily 
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highly conserved and is broadly present in most tissues. The NuRD complex has been 
shown to associate with oncogenic transcription factors to promote transcriptional 
repression of downstream targets. As an example, in promyelocytic leukemia, the 
oncogenic PML/RARα fusion protein recruits the NuRD complex through direct protein-
protein interactions to target genes including the tumor suppressor gene retinoic acid 
receptor β2, to promote gene silencing (112). In cancer, the NuRD complex has been 
associated with tumor progression or tumor suppression depending on the context (107).  
 
REST (RE1 silencing transcription factor) complex 
The RE1 silencing transcription factor, also called Neuron Restrictive Silencing 
Factor (NRSF) was first discovered as a repressor of neuronal genes containing a 23 bp 
conserved motif, known as the RE1 repressor element 1 or NRSE (113, 114). REST is 
critical for embryonic development; perturbations in REST expression or function in 
developing embryos leads to ectopic expression of neuronal genes in non-neuronal 
tissues, causing embryonic lethality (115). REST harbors three functional domains: a 
DNA binding domain containing eight zinc-finger motifs that bind to the NRSE, and two 
independent repressor domains (116). The amino terminal repressor domain interacts 
with the mSin3 corepressor that recruits HDACs (117). The carboxyl-terminal repressor 
domain interacts with the CoREST corepressor that also recruits HDACs. Like the NuRD 






LSD1 (Lysine-specific demethylase) 
 Histone methylation plays important roles in transcription and epigenetic 
regulation. LSD1, also referred to as KDM1A, is a flavin-dependent histone demethylase 
enzyme (119, 120). Identification and characterization of LSD1 demonstrated for the first 
time that the histone methylation process was a dynamic process. LSD1 functions as part 
of the NuRD or REST repressor complex, suggesting that DNA binding is essential for 
stimulating LSD1-mediated nucleosomal demethylation (121). The enzymatic reaction 
carried out by LSD1 requires the presence of protonated nitrogen on the histone tail to 
initiate demethylation, therefore limiting it to di-methylated and mono-methylated lysine 
residues as substrates. In contrast to HDACs, LSD1 functions as both a transcriptional 
coactivator and a transcriptional corepressor because of its ability to demethylate histone 
H3 lysine 4 mono or di methyl (H3K4me1/2), a mark of activation, or histone H3 lysine 9 
mono or di methyl (H3K9me1/2), a mark of repression. Knockdown or pharmacological 
inhibition of LSD1 has been shown to reduce proliferation of neuronal progenitor stem 
cells, suggesting a role for LSD1 in maintaining the balance between self-renewal and 
differentiation (122). Interestingly, LSD1 has been shown to regulate differentiation of 
fat and skeletal muscle tissues (123, 124), underscoring the functional importance of 
LSD1 in tissues of mesenchymal origin (125). LSD1 is highly expressed in sarcomas and, 
given its function in mesenchymal stem cells, it is likely that LSD1 plays a role in 
sarcoma pathogenesis (126). In line with this, a recent study demonstrated that Ewing 
sarcoma primary tumors express high levels of the LSD1 protein (127). LSD1 is also 
overexpressed in several other cancers and drives their oncogenic growth through 
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epigenetic mechanisms (128), suggesting that inhibition of LSD1 activity may be a viable 
and effective therapeutic strategy in multiple cancers.  
 
Dissertation goals 
Ewing sarcoma serves as an excellent paradigm for understanding tumorigenesis 
driven by the expression of chromosomal translocation-derived fusion oncoproteins 
because of its unique molecular genetics. Most cases of Ewing sarcomas harbor the 
t(11;22)(q24;q12) translocation encoding the aberrant transcription factor EWS/FLI. 
Besides the t(11;22), however, these tumors have simple karyotypes with no other 
demonstrable chromosomal abnormalities. EWS/FLI is therefore considered the central 
mediator of a hierarchy of transcriptional networks, upregulating and downregulating 
critical target genes, and leading subsequently to Ewing sarcoma development. The 
overarching goal of our research is to better understand the biology underlying the 
pathogenesis of Ewing sarcoma. A mechanistic understanding of how EWS/FLI achieves 
transcriptional control in Ewing sarcoma, what target genes it directly and indirectly 
regulates, what DNA motifs EWS/FLI utilizes to achieve this function and what proteins 
it interacts with will identify key nodes of transcriptional regulation utilized by EWS/FLI 
to achieve its pathogenic functions. These studies are important to the Ewing sarcoma 
field as they provide new insights into the mechanistic basis of Ewing sarcoma 
development and may provide new opportunities for therapeutic intervention. Thus, my 
thesis work has sought to address several key questions in this context: 
1. What are the translocation-based oncogenic fusions that occur in Ewing sarcoma 
tumors? Chapter 2 is a detailed review article describing the various TET/ETS 
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fusions that are pathognomonic for the disease. We also discuss rare non-
TET/ETS fusions that occur in “Ewing’s-like tumors” and highlight important 
questions that need to be answered to determine the true molecular identities of 
the “Ewing’s-like tumors.” 
2. What are the direct targets of EWS/FLI and what is the EWS/FLI response 
element on promoters of activated target genes that are critical for maintenance of 
oncogenic transformation in Ewing sarcoma? We used genomics approaches to 
identify direct targets of EWS/FLI in Ewing sarcoma. In addition to the 
previously characterized high-affinity consensus ETS site, we identified GGAA 
microsatellites as a novel EWS/FLI response element. Using the promoter of 
NR0B1, an EWS/FLI target gene critical for oncogenesis, we validated binding 
and transcriptional activation by EWS/FLI from the GGAA microsatellites. 
Bioinformatics approaches further established the specific association of GGAA-
microsatellites with upregulated EWS/FLI target genes.  This work is detailed in 
Chapter 3 of the dissertation. 
3. Can we use the presence of GGAA microsatellites as a tool to identify additional 
EWS/FLI target genes that are critical for Ewing sarcoma development and/or 
maintenance?  Can the presence of GGAA-microsatellites serve as a prognostic 
marker for Ewing sarcoma? Chapter 4 details our analysis of another GGAA-
microsatellite containing EWS/FLI upregulated target gene, GSTM4, as an 
essential gene required for oncogenesis and for chemotherapeutic resistance in 
Ewing sarcoma. This chapter further establishes a direct correlation between 
GSTM4 expression levels and survival outcome.  
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4. What is the role of GLI1, a direct upregulated target of EWS/FLI in Ewing 
sarcoma? What are critical downstream targets of GLI1 that mediate its function 
in Ewing sarcoma? Unlike the GGAA microsatellite response element, the GLI1 
promoter harbors the canonical ETS site as the EWS/FLI response element. We 
demonstrated that GLI1 is necessary for maintenance of oncogenic transformation 
in Ewing sarcoma. Global transcription profiling studies were performed to 
identify GLI1 target genes. We identified KRT17 as a critical GLI1 target gene 
and characterized a novel role for KRT17 in coordinating cellular adhesion and 
oncogenic transformation in Ewing sarcoma by regulating the AKT signaling 
pathway. These studies are presented in Chapter 5. 
5. What is the functional relationship between wild-type EWS and EWS/FLI? Does 
EWS function as a transcriptional cofactor in Ewing sarcoma? What are EWS 
target genes in Ewing sarcoma? Does the EWS transcription profile contribute 
significantly to the EWS/FLI transcription profile? Does EWS play a role in 
regulating cancer-related phenotypes in Ewing sarcoma? Chapter 6 details our 
analysis of the EWS and EWS/FLI RNA-sequencing-based transcriptional 
profiles in Ewing sarcoma. From this overlap, we identified a subset of neuronal 
genes that are repressed by EWS. The promoters of these neuronal genes harbor 
the response element for the transcriptional corepressor REST. We demonstrate 
that REST and EWS cooperate to repress the subset of neuronal genes thereby 
inhibiting full neuronal differentiation and contributing to the transdifferentiated 
phenotype of Ewing sarcoma cells. Furthermore, we demonstrate that wild-type 
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EWS functions as a tumor suppressor and, therefore, haploinsufficiency of EWS 
drives oncogenic transformation in Ewing sarcoma. 
6. Although EWS/FLI has previously been characterized largely as a transcriptional 
activator, does the significantly large EWS/FLI repressed gene signature contain 
direct repressed targets? Is transcriptional repression functionally significant to 
the disease biology? What domains within EWS/FLI are necessary for repression? 
What corepressor proteins does EWS/FLI interact with to directly repress target 
genes in Ewing sarcoma? Using genomic approaches we first identified a subset 
of direct repressed EWS/FLI targets. We validated a subset of these genes and 
identified two interesting candidate genes with tumor-suppressive properties in 
vitro and in vivo. Deletion mapping analysis was used to identify domains within 
EWS/FLI that are necessary and sufficient for direct repression. Using a candidate 
approach, we identified a role for the NuRD corepressor complex containing 
HDACs and LSD1 in EWS/FLI-mediated transcriptional repression. We further 
identified LSD1 as a novel target for therapeutic intervention in Ewing sarcoma. 
This work is detailed in Chapter 7. 
Taken together, the work presented in this dissertation highlights the 
identification of direct targets of EWS/FLI, and novel DNA-binding elements for 
EWS/FLI in Ewing sarcoma. We uncover a novel role for the EWS/FLI up-regulated 
target gene GLI1 in Ewing sarcoma oncogenesis. In addition, we unravel a previously 
unknown role for wild-type EWS in regulating the neural phenotype of Ewing sarcoma. 
Furthermore, we identify and characterize a less-well understood role for EWS/FLI in 
direct transcriptional repression of tumor suppressor genes. Finally, through detailed 
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Figure 1.1 Histology of Ewing sarcoma cells. The small round blue cell morphology of 
Ewing sarcoma tumors. The tumor cells stain blue with hematoxylin and eosin staining. 
The prevalence of blue staining is because the cells consist predominantly of nucleus, and 











Figure 1.2 Schematic of the EWS/FLI fusion protein. Wild-type EWS protein contains 
an amino-terminal domain (NTD), an RNA recognition motif (RRM), and three RGG 
repeat regions. Wild-type FLI protein contains a carboxyl-terminal ETS-type DNA 
binding domain (DNABD), and an amino-terminal activation domain (ATA) that 
overlaps a pointed (PNT) domain. The locations of the translocation breakpoints are 
indicated. EWS/FLI retains the NTD of EWS and the DNABD of FLI. Figure provided 











Figure 1.3 Transcriptional activation mutants of EWS/FLI. The DNA binding, 
transcriptional and transforming abilities of full-length EWS/FLI and various mutants 
generated by the fusion of the carboxyl-terminal FLI DNA binding domain to 
heterologous activation domains of other transcription factors. These data have been 
previously published (47, 55, 56). Data on the xenograft forming abilities of these 
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Oncogenic transformation in Ewing sarcoma is caused by EWS/FLI, an aberrant 
transcription factor fusion oncogene. Glioma-associated oncogene homolog 1 (GLI1) is a 
critical target gene activated by EWS/FLI, but the mechanism by which GLI1 contributes 
to the transformed phenotype of Ewing sarcoma was unknown. In this work we identify 
Keratin 17 (KRT17) as a direct downstream target gene upregulated by GLI1. We 
demonstrate that KRT17 regulates cellular adhesion by activating AKT/PKB (Protein 
Kinase B) signaling. In addition, KRT17 is necessary for oncogenic transformation in 
Ewing sarcoma and accounts for much of GLI1-mediated transformation function but via 
a mechanism independent of AKT signaling. Taken together, our data reveal previously 
unknown molecular functions for a cytoplasmic intermediate filament protein KRT17 in 
coordinating EWS/FLI and GLI1 mediated oncogenic transformation and cellular 
adhesion in Ewing sarcoma. 
 
Introduction 
Ewing sarcoma is a highly aggressive bone and soft tissue associated malignancy 
that affects children and young adults (1). The vast majority of these tumors are 
characterized by a t(11;22)(q24;q12) chromosomal translocation, that generates a fusion 
oncogene, EWS/FLI (2). Persistent expression of EWS/FLI is necessary for maintenance 
of the transformed phenotype in Ewing sarcoma (3-5). Previous  studies demonstrate that 
Ewing sarcoma tumors have a relatively low frequency of mutations in known oncogenes 
and tumor suppressors, supporting the concept that EWS/FLI is largely responsible for 
oncogenic transformation (6, 7). EWS/FLI functions as an aberrant transcription factor 
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and dysregulates the expression of myriad target genes (8-10). Over the years, several 
critical EWS/FLI target genes have been identified that are all necessary for maintenance 
of oncogenic transformation in Ewing sarcoma; however, no target gene alone has proven 
to be sufficient for EWS/FLI mediated oncogenic transformation (3, 4). These findings 
highlight the unique biology of Ewing sarcoma and its sole reliance on a single oncogenic 
transcription factor, EWS/FLI, as the central regulator of a hierarchy of transcriptional 
networks.  
Hedgehog signaling is of critical importance during development in regulating 
tissue patterning and stem cell maintenance (11, 12). This signaling pathway is 
inappropriately activated in a diversity of cancers (13-22). GLI1 is a zinc-finger 
transcription factor and is the principal effector of the Hedgehog signaling pathway (11). 
Previous microarray studies and a recent RNA-sequencing (RNA-seq) experiment have 
identified GLI1 as an EWS/FLI upregulated target gene in Ewing sarcoma (3, 10), 
(Sankar et al., submitted). EWS/FLI has been shown to bind and directly activate 
transcription from the GLI1 promoter (23). Furthermore, loss-of-function approaches and 
pharmacological inhibition have demonstrated that GLI1 is necessary for EWS/FLI 
mediated oncogenic transformation (23-25). These studies highlight the importance of 
GLI1 in Ewing sarcoma development. 
However, the mechanism underlying GLI1 mediated oncogenesis in Ewing 
sarcoma and the critical transcriptional network of genes regulated by GLI1 to achieve 
this function were unknown.  Here, we sought to define the mechanistic role of GLI1 in 
Ewing sarcoma, and in doing so, identified a unique target gene, KRT17 that has novel 
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functions in coordinating parallel functions of cellular adhesion and oncogenic 
transformation.  
 
Materials and methods 
Ethics statement 
Patient tumor specimens were used in a deidentified way, and were therefore 
deemed “non-human subject research” by the University of Utah Institutional Review 
Board via protocol IRB_00035414. Animal experiments were performed following 
approval from the University of Utah Institutional Animal Care and Use Committee. 
 
Constructs and retroviruses 
The Luciferase-RNAi (Luc-RNAi), EWS/FLI-RNAi (EF-2-RNAi), 3x-FLAG 
EWS/FLI and 3x-FLAG NKX2.2 cDNA have been described previously (3, 10, 26). The 
GLI1 and KRT17 shRNAs were designed to target the cDNA and 3’UTR, respectively, 
and cloned into the pMKO.1 retroviral vector. 3x-FLAG GLI1, 3x-FLAG KRT17 and 
3x-FLAG S44A KRT17 cDNAs were generated and subcloned into the Murine Stem Cell 
Virus (MSCV) retroviral vector (Clontech). One kilobase KRT17 promoter including the 
5’UTR was cloned into the pGL3 basic vector (Promega), immediately upstream of the 
luciferase reporter gene. The constitutively active (myristoylated) AKT in the MSCV 







Ewing sarcoma cell lines (A673, TC-71, TC-32, SK-N-MC and EWS502) and 
HEK293 EBNA cells were infected with retrovirus, and polyclonal populations were 
grown in the appropriate selection media, as previously described (4, 28). Growth assays 
(3T5) were performed as previously described (28).  
 
Soft agar and methylcellulose assays 
Soft agar assays were performed as described previously (28). Methylcellulose 
assays were performed by plating 1x105 cells in 2% methylcellulose mixed with an equal 
volume of appropriate growth media as described previously (29). 
 
Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) 
Total RNA was extracted using an RNAeasy kit (Qiagen). Total RNA from cells 
was then amplified and detected using SYBR green fluorescence for quantitative 
analysis. Normalized fold enrichment was calculated by determining the fold-change of 
each condition relative to the control (either Luc-RNAi or Luc-RNAi re-expressing an 
empty vector). The data in each condition was then normalized to internal housekeeping 
control genes GAPDH and RPL19. Primer sequences used to amplify target genes by 
qRT-PCR are provided in Supplemental Data (Table S5.1). 
 
Luciferase reporter assays 
A one kilobase promoter region including the 5’UTR of KRT17 was cloned into 
the pGL3 basic vector (Promega) immediately upstream of the luciferase reporter gene. 
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Luciferase reporter assays were performed in HEK293 EBNA as previously described 
(30). 
 
Xenograft and intratibial injection assays 
A673 cells infected and selected with a control ERG-RNAi or KRT17-RNAi were 
injected into the flanks of nude mice at 1 × 106 cells per flank or 2.5 x 105 cells into the 
tibia of NOD/SCID mice. For the xenograft tumor assay, four mice were injected 
subcutaneously with control knockdown cells and five mice were injected subcutaneously 
with KRT17 knockdown cells. Both flanks of each mouse was injected subcutaneously, 
therefore, eight and ten tumors were measured for the two groups, respectively. For the 
intratibial tumor assay, five mice were each injected in the right tibia; therefore, five 
tumors were measured per group. Tumors were measured using digital calipers and three-
dimensional tumor volumes were calculated using the equation (Length x Width x 
Depth)/2. The mice in each group were sacrificed once their tumors reached a size limit 
of 2 cm for the subcutaneous injection model and 1.5 cm for the intratibial injection 
model. The data from both assays are plotted as Kaplan-Meier survival curves using 
GraphPad Prism. 
 
Antibodies and reagents 
The following antibodies were used for immunodetection: M2-anti-FLAG (HRP; 
Sigma A8592), anti-FLI-1 (Santa-Cruz sc-356X), antiα-Tubulin (Calbiochem CP06), 
anti-KRT17 (Abcam ab-53707) and anti-phospho AKT (S473) (Cell Signaling # 9271S), 
anti-AKT (pan) (Cell Signaling # 4691S), anti-GLI1 (Cell Signaling # 2643S). The 
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isozyme selective AKT inhibitor (Akti1/2) was obtained from Millipore Cat. No.124017. 
The inhibitor was used at a final concentration of 2 µM. At this concentration it inhibits 
all three forms of AKT (AKT1, AKT2 and AKT3). Cells were treated with the inhibitor 
for twenty four hours before they were used for experiments.  
 
Adhesion and migration assays 
Ewing sarcoma cells infected and selected with different constructs were seeded 
at 5 x105 cells per well in a non-ECM coated 24-well plate. Cells were allowed to adhere 
for two hours at 37ºC and then were processed as previously described (31). Cells that 
adhered were stained with Toluidine Blue and O.D. was measured at 620nm as 
previously described. Cell migration was measured using the Boyden Chamber 
haptotactic cell migration assay as previously described (31). 
 
Immunofluorescence assays 
Sterile coverslips were coated with 10 µg/ml fibronectin in 12-well plates 
overnight at 4ºC. 75 x 103 cells/well were seeded, allowed to adhere for twenty four 
hours, fixed with 3.7% formaldehyde as described previously (31). Cells were stained 
with anti-paxillin antibody (1:100) for one hour at 37ºC and then with AlexaFluor 
secondary antibody (1:200) and AlexaFluor-phalloidin and were imaged using a Zeiss 






RNA sequencing analysis, GSEA and Venn overlaps 
RNA from A673 cells stably infected and selected for expression of a control 
Luc-RNAi or the KRT17-RNAi was extracted using the RNAeasy kit (Qiagen) with an 
on-column DNAse digestion protocol. Libraries for deep-sequencing were prepared 
according to the manufacturer’s instructions (Illumina) and sequenced on an Illumina Hi-
Seq with 50 cycles of single end reads.  Sequences were aligned to the human genome 
build hg19. Raw sequence reads can be found in the NCBI SRA #121863. The USeq 
analysis package was used to identify differentially expressed genes. Significance 
parameters were set to a two-fold or four-fold change in expression and an FDR of 0.1 
(10%) or 1.0 x 10-10.  
Overlaps between the different gene sets were performed using the VennMaster   
program. Statistical significance of the overlaps was determined using Chi square 
analysis. Gene set enrichment analysis (GSEA) was performed using GSEA v2.0.10 
program. Functional annotation analysis was performed by Database for Annotation, 
Visualization and Integrated Discovery (DAVID) analysis. Identification of potential 




GLI1 is a downstream target of EWS/FLI and is necessary for oncogenic  
transformation 
Previous studies using loss of function approaches have identified GLI1 as an 
upregulated target of EWS/FLI (24, 25). To further demonstrate that GLI1 is specifically 
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regulated by EWS/FLI, we used a retroviral-based stable knockdown/rescue approach in 
A673 cells (a patient-derived Ewing sarcoma cell line). We found that reduction of 
EWS/FLI resulted in a significant reduction in GLI1 expression, which was restored by 
reexpression of an RNAi-resistant EWS/FLI cDNA (Figure 5.1A, S5.1A). This result 
demonstrated that GLI1 is specifically upregulated by EWS/FLI and is not an off-target 
or other nonspecific RNAi effect. EWS/FLI did not regulate GLI2 or GLI3 (Figure 
S5.1B). GLI1 is not the sole downstream effector of EWS/FLI-mediated oncogenic 
transformation because GLI1 expression (Figure 5.1B) failed to rescue oncogenic 
transformation following knockdown of EWS/FLI (Figure 5.1C). 
To test the necessity of GLI1 in Ewing sarcoma oncogenesis, we performed GLI1 
knockdown/rescue experiments (Figure 5.1D, S5.1C). In comparison to a control 
knockdown (Luc-RNAi) GLI1 knockdown did not affect monolayer growth of cells in 
tissue culture but significantly reduced colony growth in soft agar (Figures 5.1E, 5.1F). 
This is not an “off-target” effect because reexpression of GLI1 rescued the loss of 
transformation induced by GLI1 knockdown (Figure 5.1D-5.1F). These results 
demonstrated that GLI1 is necessary for maintenance of oncogenic transformation in 
Ewing sarcoma cells.  
GLI1 has been shown to transcriptionally activate NKX2.2 (25). NKX2.2 is a 
critical target of EWS/FLI that is necessary for oncogenic transformation in Ewing 
sarcoma (3). We therefore asked if NKX2.2 could rescue GLI1-knockdown mediated loss 
of transformation. Interestingly, we found that NKX2.2 (Figure S5.1D) was unable to 
rescue the loss of transformation mediated by GLI1-knockdown (Figure 5.1F), indicating 
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that other GLI1 target genes are necessary for full oncogenic transformation in Ewing 
sarcoma.  
 
Determining the transcriptional signature of GLI1 in Ewing sarcoma 
We next sought to identify the full-complement of genes regulated by GLI1 in 
Ewing sarcoma. We performed an RNA-seq experiment in A673 cells comparing 
genome-wide transcripts from cells expressing a control or GLI1-RNAi constructs 
(Figure 5.2A, Table S5.2). Venn master analysis was used to generate overlaps of the up-
regulated and downregulated genesets obtained from the GLI1 RNA-seq and the 
EWS/FLI RNA-seq (Sankar et al., submitted). Of the 1796 genes upregulated by 
EWS/FLI, 327 genes were also upregulated by GLI1 (p=3.19 x 10-162; Figure 5.2B), and 
of the 2227 genes repressed by EWS/FLI, 319 genes were also repressed by GLI1 
(p=1.01 x 10-170; Figure 5.2B), demonstrating that GLI1 contributes significantly to the 
EWS/FLI transcriptional profile in Ewing sarcoma cells. Using very stringent cutoffs of a 
four-fold change and an FDR of 1.0 x 10-10 we limited the list to 86 genes upregulated 
and 55 genes downregulated by GLI1 (Table S5.2). We used this stringent set of genes to 
perform Gene Set Enrichment Analysis (GSEA) against EWS/FLI-regulated genes to 
better determine the relationship between the EWS/FLI and GLI1 transcriptional profiles. 
We found that the GLI1 upregulated genes clustered strongly with the most highly 
upregulated EWS/FLI genes (NES=2.0; p<0.001) and vice-versa (NES=-1.8; p<0.001) 
(Figure 5.2C), indicating that GLI1-regulated genes make up a significant portion of the 
EWS/FLI transcriptional signature. We performed similar analyses using microarray 
datasets generated from TC71 and EWS502 Ewing sarcoma cells and again found 
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significant correlations between GLI1 and EWS/FLI in gene regulation (Figure S5.2A 
and S5.2B). We also validated a subset of GLI1-regulated genes identified in the RNA-
seq data by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) 
(Figure S5.2C). 
To gain further insight into the functional significance of the differentially 
expressed genes from the GLI1 RNA-seq, we used the functional annotation tools from 
the Database for Annotation, Visualization and Integrated Discovery (DAVID). We 
found that the most significant classes among the GLI1 upregulated genes corresponded 
to neuronal development and cell cycle regulation (Figure 5.2D), which is consistent with 
the well-studied role of GLI1 in neuronal development (32) and its ability to 
transcriptionally regulate cell cycle proteins (33). Interestingly, neuronal features have 
previously been noted in Ewing sarcoma (34, 35), and thus the RNA-seq data suggests 
that GLI1 and its downstream target genes may contribute to the neuronal phenotype of 
Ewing sarcoma. Among the downregulated geneset, the most significant classes were 
related to signaling and membrane activity (Figure 5.2D).  
 
Identification of KRT17 as a direct downstream target of GLI1 
To further investigate the role of GLI1 target genes identified from the RNA-seq 
analysis, we focused on KRT17, which is the second most upregulated GLI1 target gene 
(Figure 5.2A) and is also regulated by EWS/FLI (Figure 5.2B, 5.2C, S5.2A, S5.2B). 
qRT-PCR analysis demonstrated that both GLI1 and EWS/FLI upregulate KRT17 in 
multiple Ewing sarcoma cell lines (Figure 5.3A, 5.3B, and 5.3C). Western blot analysis 
revealed that the KRT17 protein is expressed at detectable levels in all Ewing sarcoma 
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cell lines tested, albeit, at varying levels (Figure 5.3D), and KRT17 RNA is expressed in 
five independent Ewing sarcoma primary tumors (Figure 5.3E). These results 
demonstrate that KRT17 is an up-regulated target of GLI1 in Ewing sarcoma. 
The GLI1 RNA-seq analysis does not distinguish direct from indirect targets. 
GLI1 is a well-studied transcription factor, and previous work has identified and 
characterized a conserved 10-base pair motif as the preferred binding site 
(GACCACCCAC/A) for GLI1 on target gene promoters (36, 37). To predict potential 
direct targets of GLI1, we used Find Individual Motif Occurrences (FIMO) (38), by 
combining a previously published weighted matrix for binding affinity and a weighted 
matrix for activation potential of GLI1 at the 10-base pair motif, to search for genes in 
our RNA-seq dataset that had a significant match (p-value cut-off of 1.0 x 10-5) to the 
known GLI1 binding motif. We identified 23 potential direct upregulated and 12 direct 
downregulated targets of GLI1 (Figure S5.3). Interestingly, KRT17 was one of the 
potential direct targets of GLI1 (Figure S5.3, Table 1). Luciferase reporter assays 
demonstrated a dose-dependent increase in luciferase activity from a 1Kb KRT17 
promoter region with increasing concentrations of the GLI1 cDNA (Figure 5.3F). These 
data indicate that KRT17 is likely a direct upregulated target of GLI1. 
 
KRT17 is necessary for oncogenic transformation in vitro and in vivo 
KRT17 is a cytoplasmic intermediate filament protein (39) that is overexpressed 
in several cancers (40-46). High KRT17 expression correlates with poor prognosis in 
breast, pancreatic and gastric adenocarcinomas (47-49). In basal cell carcinomas, which 
are associated with aberrant hedgehog signaling, KRT17 promotes tumor growth by 
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modulating the immune response (40). However, it is unknown whether KRT17 plays a 
more direct role in oncogenic transformation. 
To determine if KRT17 is involved in oncogenic transformation in Ewing 
sarcoma, we performed knockdown/rescue of KRT17 in A673, EWS502 and SK-N-MC 
Ewing sarcoma cells. We found that knockdown of KRT17 had no effect on cell growth 
in tissue culture, but significantly reduced colony formation  in soft agar (Figure 5.4A, 
5.4B, 5.4C, 5.4D, S5.4A, and S5.4B). Furthermore, reexpression of KRT17 in 
knockdown cells restored their ability to form colonies in soft agar, demonstrating a 
specific function of KRT17 in maintaining the transformed phenotype of Ewing sarcoma 
cells (Figure 5.4D, 5.4E). Importantly, qRT-PCR analysis of endogenous KRT17 
transcript levels demonstrated that the KRT17 knockdown was maintained even in the 
KRT17 cDNA rescue samples (Figure S5.4D), suggesting that rescue of oncogenic 
transformation was not merely due to loss of the KRT17-RNAi. KRT17 knockdown had 
no effect on oncogenic transformation in the non-Ewing sarcoma cell line HEK293 
EBNA (human embryonic kidney cells) (Figure S5.4C), suggesting that KRT17 is 
specifically required for oncogenic transformation in Ewing sarcoma. 
We next used two in vivo tumor models, a subcutaneous model and an orthotopic 
intratibial model, to evaluate the role of KRT17 in tumor growth in vivo. We noted a 
significant improvement in overall survival of immunocompromised mice injected with 
KRT17 knockdown A673 cells when compared to those with control (ERG) knockdown 
cells in both in vivo models (Figure 5.4F). In the tumors that did form in mice injected 
with KRT17 knockdown cells, we noted that the knockdown effect was lost in tumors 
that grew actively, while the slow growing (indolent) tumors from the opposite flanks of 
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those mice still maintained the KRT17 knockdown (Figure 5.4G), indicating that KRT17 
is necessary for aggressive tumor growth in vivo. 
To evaluate if KRT17 was a critical target gene downstream of GLI1, we 
performed anchorage-independent colony forming assays with A673 cells following 
control or GLI1 knockdown and re-expressing an empty vector, GLI1 or KRT17 cDNA 
constructs (Figure 5.4H). Surprisingly, expression of the KRT17 cDNA rescued GLI1 
knockdown mediated loss of transformation (Figure 5.4I). In cells harboring the GLI1-
RNAi and re-expressing the KRT17 cDNA, maintenance of GLI1 knockdown and lack of 
rescue of GLI1 target genes was demonstrated by qRT-PCR analysis (Figure S5.4E, 
S5.4F), indicating that rescue of oncogenic transformation was not due to reexpression of 
GLI1 when KRT17 is expressed. Taken together these results demonstrate that KRT17 is 
necessary for maintaining the transformed phenotype of Ewing sarcoma cells both in 
vitro and in vivo, and that KRT17 is a critical target gene downstream of GLI1 that 
contributes significantly to GLI1 mediated maintenance of oncogenic transformation in 
Ewing sarcoma. 
 
KRT17 mediated activation of AKT signaling is necessary and sufficient to regulate 
cellular adhesion in Ewing sarcoma 
KRT17 is known to regulate protein synthesis and epithelial cell growth by 
inducing phosphorylation and activation of the AKT protein (50). We therefore asked 
whether KRT17 regulated AKT phosphorylation downstream of GLI1, and if this genetic 
interaction was necessary for KRT17 function in Ewing sarcoma. GLI1 knockdown 
significantly reduced AKT phosphorylation levels in A673 cells, and this effect was 
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rescued by GLI1 or KRT17 reexpression (Figure 5.5A), but not KRT17 S44A (Figure 
5.5B), a previously described mutant that fails to induce phosphorylation of AKT (50, 
51), demonstrating that KRT17 is the critical mediator of AKT phosphorylation 
downstream of GLI1. 
To characterize the functional significance of KRT17 mediated activation of AKT 
signaling, we performed immunofluorescence studies on A673 cells expressing reduced 
levels of KRT17. Interestingly, we noted a significant decrease in staining for Paxillin 
protein, a marker of focal adhesions, in the cells expressing reduced KRT17 levels in 
comparison to control cells (Figure 5.5C). As a control, EWS/FLI knockdown cells 
expressed higher levels of Paxillin (Figure 5.5C) as noted previously (31). To test if 
KRT17 is directly involved in regulating cellular adhesion in Ewing sarcoma cells, we 
performed cellular adhesion assays with KRT17 knockdown cells re-expressing wild-
type KRT17 or the S44A mutant. Interestingly, wild-type KRT17, but not the S44A 
mutant, rescued basal levels of cellular adhesion in Ewing sarcoma cells (Figure 5.5D).  
To directly test the contribution of active AKT signaling in cellular adhesion 
mediated by KRT17, we took two complementary approaches: (i) a genetic approach by 
expressing a constitutively active form of AKT (myristoylated AKT) (27), and (ii) a 
pharmacological approach using a selective AKT inhibitor (Akti1/2; Millipore). We 
found that expression of the constitutively active AKT following knockdown of 
endogenous KRT17 (Figure 5.5E) phenocopied KRT17 mediated cellular adhesion 
(Figure 5.5F). We also found that selective inhibition of AKT by the pharmacological 
inhibitor significantly decreased the basal levels of cellular adhesion in Ewing sarcoma 
cells, similar to levels achieved with KRT17 knockdown (Figure 5.5G). These data 
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clearly define the genetic and functional interaction between GLI1, KRT17 and active 
AKT signaling in regulating cellular adhesion in Ewing sarcoma cells. 
 
KRT17 mediated oncogenic transformation is independent of the  
AKT pathway 
AKT signaling is frequently activated in cancer (52). We therefore asked whether 
AKT phosphorylation was necessary for KRT17 mediated oncogenic transformation in 
Ewing sarcoma. Interestingly, the KRT17 S44A mutant that failed to phosphorylate AKT 
(Figure 5.5B) retained the ability to rescue KRT17 knockdown mediated loss of 
transformation to an extent comparable to wild-type KRT17 (Figure 5.6A), suggesting 
that oncogenic transformation by KRT17 is independent of the AKT pathway. 
To directly test the contribution of active AKT signaling in Ewing sarcoma 
oncogenesis, we used the constitutively active form of AKT (myristoylated AKT) (27), 
and the selective AKT inhibitor (Akti1/2; Millipore). The constitutively active form of 
AKT failed to rescue the loss of oncogenic transformation following KRT17 knockdown, 
even though high levels of AKT phosphorylation were achieved (Figure 5.6B, 5.5E). 
Pharmacological inhibition of AKT phosphorylation also had no effect on oncogenic 
transformation of Ewing sarcoma cells (Figure 5.6C). Maintenance of AKT inhibition in 
the anchorage-independent environment was ensured by assessing the phosphorylation 
status of AKT in the colonies that did form (Figure 5.6D). These results suggest that 
AKT signaling is completely dispensable to the anchorage-independent colony-forming 
phenotype of Ewing sarcoma cells. Taken together, our data highlight a central role for 
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KRT17 downstream of GLI1 in coordinating two important, but independent, phenotypes 
of cancer cells, oncogenic transformation and cellular adhesion. 
 
Discussion 
In this work we identified KRT17 as an upregulated target of EWS/FLI and GLI1 
in Ewing sarcoma. Furthermore, we unraveled novel functional roles for KRT17 in 
regulating oncogenic transformation and cellular adhesion in Ewing sarcoma: KRT17 
induces AKT signaling to mediate cellular adhesion, while KRT17 modulates oncogenic 
transformation (as measured by colony formation in anchorage-independent conditions 
and by xenograft tumor formation) independent of AKT signaling. To our knowledge, 
this is the first demonstration of such a coordinating function for an intermediate-filament 
protein for these cancer-relevant phenotypes. 
Hyperactive AKT signaling is characteristic of several cancers (52). Interestingly, 
oncogenic transformation mediated by KRT17 is independent of the AKT signaling 
pathway in Ewing sarcoma. Consequently, inhibiting the AKT signaling pathway had no 
impact on growth or oncogenic transformation of Ewing sarcoma cells. These 
observations suggest that cooperating molecules or pathways necessary for AKT to 
mediate oncogenic transformation in other cancers may be absent in Ewing sarcoma 
cells. Indeed, polymerization of KRT17 with KRT5/6α/6β is required to form stable 
cytoskeletal structures (39), and mutations in KRT17 or its partners KRT5, 6α or 6β 
result in human genetic diseases. We inspected our global transcriptional profiling 
datasets and found very low, if any, expression for KRT5, 6α or 6β in Ewing sarcoma 
cells, suggesting that KRT17 functions in a novel capacity to regulate oncogenic 
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transformation. This also indicates that in addition to regulating AKT signaling, KRT17 
might impinge on multiple critical growth factor signaling pathways in the context of 
Ewing sarcoma cells - all of which together contribute to the transformed phenotype. 
Further studies are ongoing to identify the precise mechanism by which KRT17 regulates 
oncogenic transformation in Ewing sarcoma. 
Importantly, we demonstrate in this report that KRT17-mediated AKT 
phosphorylation is necessary and sufficient for regulating cellular adhesion. There is a 
growing body of evidence indicating that alterations in the adhesion properties of cells 
play a pivotal role in the development and progression of cancer (53). Expression of 
EWS/FLI has profound effects on adhesion and cytoskeletal architecture of Ewing 
sarcoma cells (31). In support of this are transcriptional profiling data for EWS/FLI in 
Ewing sarcoma cells that reveal significant downregulation of adhesion and cytoskeletal 
proteins, suggesting that Ewing sarcoma cells have low basal levels of cellular adhesion 
(10). In fact cellular adhesion is dramatically increased upon EWS/FLI knockdown in 
Ewing sarcoma cells (31). Ewing sarcoma is a highly metastatic tumor and in the absence 
of chemotherapy, the vast majority of patients die from metastatic disease, suggesting 
that most patients have micrometastases at presentation (54, 55). In support of this, 
circulating tumor cells can be identified in Ewing sarcoma patients (56). These 
observations suggest that, in contrast to epithelial cancers, which are thought to follow a 
multistep process for metastasis, a mesenchymal tumor like Ewing sarcoma may display 
metastatic dissemination of tumor cells early in the disease process (31). The ability of 
Ewing sarcoma tumor cells to readily disseminate clearly highlights the importance of 
regulating adhesion levels in these tumors. Although EWS/FLI largely inhibits cellular 
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adhesion proteins likely to promote metastatic dissemination in Ewing sarcoma, these 
tumor cells still need to maintain low basal levels of adhesion to be able to form tumors, 
and to adhere to and colonize secondary sites of metastasis. Our data suggests that 
KRT17 is one of the critical cytoskeletal proteins, downstream of EWS/FLI and GLI1 
that is necessary to maintain basal levels of cellular adhesion in Ewing sarcoma by 
activating the AKT signaling pathway. Interestingly, the AKT signaling pathway has 
been previously shown to activate Focal Adhesion Kinase (FAK)-dependent adhesion in 
cancer (57) further supporting our finding that AKT signaling regulates cellular adhesion 
in Ewing sarcoma.  
Our data in this study suggest that AKT-signaling uncouples KRT17-mediated 
cellular adhesion and oncogenic transformation in Ewing sarcoma. A similar uncoupling 
of cellular adhesion and oncogenic transformation has previously been noted in activated 
Src kinase signaling. Src kinase expression/activity is frequently increased in various 
cancers where it affects oncogenic transformation by activating RAS, PI3K and STAT 
signaling pathways (58). Activated mutants of Src play a role in oncogenic 
transformation and affect morphological changes including cellular adhesion (59). 
Interestingly it has been shown that integrin α5β3 signaling regulates Src-kinase mediated 
oncogenic transformation but this interaction does not affect Src-mediated cellular 
adhesion (60). Our data suggest that signaling downstream of KRT17 may occur through 
multiple independent pathways, one of which is AKT signaling, that is necessary for 
cellular adhesion but dispensable for oncogenic transformation.  
Based on our findings, we would hypothesize that inhibiting the AKT signaling 
pathway alone would be an ineffective therapy for Ewing sarcoma patients. In support of 
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this are findings that Insulin-like Growth Factor 1 Receptor (IGF1R) antagonists that 
have shown efficacy in Phase I/II clinical trials for the treatment of Ewing sarcoma 
patients (61, 62) inhibit not only the PI3K-AKT signaling but also the RAS-MAPK and 
JAK-STAT pathways. Therefore, inhibiting multiple crucial signaling pathways may be 
necessary to inhibit growth and transformation of Ewing sarcoma cells. Also, targeting 
pathways downstream of IGF1R, with MEK/MAPK inhibitors (PD98059 and U0126) 
and the PI3K inhibitor (LY294002) decreases Ewing sarcoma cell survival and increases 
sensitivity to doxorubicin (63). Interestingly, blocking AKT activation alone did not have 
any effect on survival or proliferation of Ewing sarcoma cells (Sankar, unpublished 
observations). Our results demonstrate that active AKT signalling is not required for 
proliferation or oncogenic transformation in Ewing sarcoma. 
In conclusion, we have defined a new pathway downstream of GLI1 in Ewing 
sarcoma that highlights the central role of KRT17 in coordinating both oncogenic 
transformation and cellular adhesion in Ewing sarcoma. Future work will be required to 
identify the critical factors and pathways downstream of KRT17 that affect oncogenic 
transformation. These studies will be key to a better understanding of the biology of 
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Figure 5.1 GLI1 is upregulated by EWS/FLI and is necessary for oncogenic 
transformation in Ewing sarcoma cells. (A) Western blot analysis to demonstrate 
EWS/FLI mediated activation of GLI1. GLI1 and EWS/FLI levels were assessed in A673 
cells infected with a control shRNA (Luc) or an shRNA targeting EWS/FLI followed by 
rescue with an empty vector or an RNAi-resistant EWS/FLI cDNA using anti-GLI1 and 
anti-FLI antibodies. Tubulin was used as a loading control. (*) indicates the 3x-FLAG 
tagged EWS/FLI cDNA that runs slightly higher than endogenous EWS/FLI. (B) Western 
blot analysis to demonstrate expression of the RNAi-resistant 3x-FLAG tagged EWS/FLI 
cDNA or 3x-FLAG tagged GLI1 cDNA constructs using an anti-FLAG antibody in A673 
cells expressing a control shRNA (Luc) or an EWS/FLI shRNA. Tubulin was used as the 
loading control. (C) Quantification of colonies formed by A673 cells described in (B). 
Error bars indicate SD of duplicate assays. P-values were determined using a student’s t-
test comparing all conditions to the control knockdown/empty vector condition (*** for 
p≤0.001). (D) Western blot analysis of GLI1 levels in A673 cells infected with a control 
shRNA (Luc) or an shRNA targeting GLI1 followed by rescue with an empty vector or 
an RNAi-resistant GLI1 cDNA. Tubulin was used as a loading control. (*) indicates the 
3x-FLAG tagged GLI1 cDNA that runs slightly higher than endogenous GLI1. (E) 
Growth assays (3T5) for A673 cells described in (D). Student’s t-test showed no 
significant difference in growth curves. (F) Quantification of colonies formed in soft agar 
by A673 cells expressing a control shRNA (Luc) or a GLI1 shRNA, re-expressing an 
empty vector or an RNAi-resistant GLI1 or NKX2.2 cDNA constructs. Error bars 
indicate SD of duplicate assays. P-values were determined using a student’s t-test 





Figure 5.2 GLI1 regulates a significant portion of the EWS/FLI transcription profile in 
Ewing sarcoma cells. (A) Heat map representation of the rank-ordered expression 
profiling data from the GLI1 RNA-seq. Genes were ranked by mean deviation of the log 
transformed FPKM (Fragments Per Kilobase per Million mapped reads). Each row 
represents a different gene. The top 15 upregulated (left) and downregulated (right) genes 
from the GLI1 RNA-seq are shown. (B) Venn diagram representations of the overlap 
between the EWS/FLI and the GLI1 transcription profiles, both generated by RNA-seq in 
A673 cells. The Chi square-determined p-values are indicated. (C) Gene set enrichment 
analysis (GSEA) using the EWS/FLI regulated genes in A673 cells (RNA-seq) as the 
rank-ordered dataset and the 86 Gli1 upregulated and 55 GLI1-downregulated genesets 
(RNA-seq). The positions of the 86 and 55 GLI1 genes are indicated as black vertical 
lines in the center portion of the panel. The normalized enrichment scores (NES) and p-
values are shown. (D) Top ten categories identified by DAVID functional analysis of the 
GLI1 up and downregulated genesets. The log transformed enrichment scores for each 








Figure 5.3 KRT17 is regulated by GLI1 in multiple Ewing sarcoma cell lines. (A) 
Validation of KRT17 being an EWS/FLI and GLI1 target gene. qRT-PCR analysis of 
KRT17 in A673 cells infected with a control shRNA (Luc), an EWS/FLI shRNA or a 
GLI1 shRNA, followed by rescue with an empty vector, an RNAi-resistant EWS/FLI 
cDNA or a GLI1 cDNA construct. Error bars indicate SD. P-values were determined 
using a student’s t-test comparing all conditions to the control knockdown/empty vector 
condition (** for p≤0.01; *** for p≤0.001). (B) Western blot analysis of cells described 
in (A) using KRT17, EWS/FLI and GLI1 antibodies. Tubulin was used as the loading 
control. (*) indicates the 3x-FLAG tagged EWS/FLI and GLI1 cDNAs. (C) qRT-PCR 
validation of KRT17 being a GLI1 target gene in multiple patient-derived Ewing sarcoma 
cell lines (TC71, TC32, SK-N-MC and EWS502). Cells were infected with a control 
shRNA (Luc) or a GLI1 shRNA. GLI1 and KRT17 mRNA levels were analyzed. Error 
bars indicate SD. P-values were determined using a student’s t-test comparing all 
conditions to the control knockdown (Luc-shRNA) (** for p≤0.01; *** for p≤0.001). (D) 
Western blot analysis of KRT17 expression in multiple patient-derived Ewing sarcoma 
cell lines (A673, TC71, TC32, SKNMC, SKES1 and EWS502). Tubulin was used as the 
loading control. (E) RT-PCR analysis of KRT17 transcript levels in five independent 
Ewing sarcoma patient tumor samples compared to KRT17 transcript levels in A673 cells 
infected with a control shRNA (Luc) or a KRT17 shRNA as well as a water negative 
control. (F) Luciferase reporter assay in HEK293 EBNA cells cotransfected with a 1 Kb. 
KRT17 promoter region upstream of luciferase or a control vector (that does not contain 
the KRT17 promoter) and an empty vector or increasing concentrations of the GLI1 
cDNA. Relative luciferase activity is the ratio of firefly luciferase activity to Renilla 
luciferase activity (to control for transfection efficiency). Error bars indicate SD. P-values 
were determined using a student’s t-test comparing all GLI1 cDNA transfected 








Figure 5.4 KRT17 is necessary for GLI1 mediated oncogenesis in Ewing sarcoma. (A) 
shRNA knock-down of KRT17 in A673 cells infected with a control shRNA (Luc) or two 
different shRNA constructs targeting KRT17, measured by qRT-PCR.  Error bars 
indicate SD. P-values were determined using a student’s t-test comparing all conditions 
to the control knockdown (Luc-shRNA) (** for p≤0.01; *** for p≤0.001). (B) Western 
blot analysis of KRT17 in cells described in (A). Tubulin was used as the loading control. 
(C) Growth assays (3T5) for A673 cells described in (A). Student’s t-test showed no 
significant difference in growth curves. (D) Quantification of colonies formed in 
methylcellulose by A673 cells expressing a control shRNA (Luc) or two different KRT17 
shRNAs, re-expressing an empty vector or an RNAi-resistant KRT17 cDNA construct. 
Error bars indicate SD of duplicate assays. P-values were determined using a student’s t-
test comparing all conditions to the control knockdown/empty vector condition (** for 
p≤0.01). (E) Western blot analysis of cells described in (D). The KRT17 blot 
demonstrates maintenance of KRT17 knockdown in cells infected with two independent 
KRT17 shRNAs and re-expressing an empty vector control, compared to control cells. 
The FLAG blot demonstrates expression of the RNAi-resistant KRT17 cDNA construct. 
(F) Survival curves for immunodeficient mice subject to subcutaneous or intratibial 
injections with A673 cells expressing a control shRNA (ERG) or a KRT17 shRNA. Five 
mice were used per condition. For the subcutaneous model, both flanks of each mouse 
was injected subcutaneously. In the control condition one mouse died due to the 
anesthesia and was censored from the analysis. Therefore 8 and 10 tumors were measured 
for the control knockdown and KRT17 knockdown groups, respectively. For the 
intratibial model, the right tibia of each mouse was injected, and therefore, 5 tumors were 
measured for each group. The mice in each group in the subcutaneous model were 
sacrificed once their tumors reached a size limit of 2 cubic cm. The mice in each group in 
the intratibial model were sacrificed once their tumors reached a size limit of 1.5 cubic 
cm. Percent survival was plotted for both models as Kaplan-Meier survival curves using 
GraphPad Prism. The log-rank (Mantel-Cox Test) determined p-values using GraphPad 
Prism are indicated. (G) Western blot analysis of control (ERG) shRNA or KRT17 
shRNA expressing tumors from the subcutaneous injection model described in (F). 
KRT17 levels in the tumors were compared to levels in the parental A673 cells 
expressing either the control shRNA or KRT17 shRNA, used to inject mice. Tubulin was 
used as the loading control. (H) Western blot analysis of A673 cells expressing a control 
shRNA (Luc) or a GLI1 shRNA and re-expressing an empty vector, 3x-FLAG tagged 
GLI1 or 3x-FLAG tagged KRT17 cDNA constructs using a FLAG antibody. Tubulin was 
used as the loading control. (I) Quantification of colonies formed in methylcellulose by 
A673 cells described in (H). Error bars indicate SD of duplicate assays. The P-value was 
determined using a student’s t-test comparing the GLI1 knockdown/empty vector 








Figure 5.5 KRT17 is necessary and sufficient for AKT phosphorylation mediated cellular 
adhesion in Ewing sarcoma cells. (A) Western blot analysis of A673 cells infected with a 
control shRNA (Luc) or the GLI1 shRNA and re-expressing an empty vector, GLI1 or 
KRT17 cDNA constructs. The protein lysate from these cells were probed with 
phosphorylated-AKT (S473), total AKT and FLAG antibodies. Tubulin was used as a 
loading control. (B) Western blot analysis of A673 cells infected with a control shRNA 
(Luc) or a KRT17 shRNA and re-expressing an empty vector, KRT17 wild-type or an 
S44A mutant KRT17 cDNA construct. The protein lysate from these cells were probed 
with phosphorylated-AKT (S473), total AKT and KRT17 antibodies. (*) indicates 3x-
FLAG tagged KRT17 and 3x-FLAG tagged S44A KRT17 cDNA constructs, which run 
slightly higher than endogenous KRT17. Tubulin was used as a loading control. (C) 
Immunofluorescence images of A673 cells infected with a control shRNA (Luc), KRT17 
shRNA or an EWS/FLI shRNA stained for focal adhesions (paxillin antibody) and for 
actin filaments (phalloidin). Arrow heads indicate paxillin-rich focal adhesions. (D) 
Adhesion assay with A673 cells infected with a control shRNA (Luc) or a KRT17 
shRNA, re-expressing an empty vector, KRT17 wild-type or S44A mutant KRT17 cDNA 
constructs. Error bars indicate SD. P-values were determined using a student’s t-test 
comparing all conditions to the control knockdown/empty vector condition (*** for 
p≤0.001). (E) Western blot analysis of A673 cells infected with a control shRNA (Luc) or 
a KRT17 shRNA and re-expressing an empty vector, KRT17 cDNA or a constitutively 
active (myristoylated) form of AKT. The protein lysate from these cells were probed with 
KRT17, phosphorylated-AKT (S473) and total AKT antibodies. Tubulin was used as a 
loading control. (F) Adhesion assay with A673 cells described in (E). Error bars indicate 
SD. The P-value was determined using a student’s t-test comparing the KRT17 
knockdown/empty vector condition to the control knockdown/empty vector condition 
(*** for p≤0.001). (G) Adhesion assay with A673 cells treated with the selective AKT 
inhibitor or vehicle control for 24 hours. Error bars indicate SD. The P-value was 
determined using a student’s t-test comparing the inhibitor treated condition to the 








Figure 5.6 KRT17 mediated oncogenic transformation is independent of AKT signaling. 
(A) Quantification of colonies formed in methylcellulose by A673 cells infected with a 
control shRNA (Luc) or a KRT17 shRNA and re-expressing an empty vector, KRT17 
wild-type or the S44A mutant KRT17 cDNA construct. Error bars indicate SD of 
duplicate assays. The P-value was determined using a student’s t-test comparing the 
KRT17 knockdown condition rescued with an empty vector to the control knockdown 
condition rescued with an empty vector (*** for p≤0.001). (B) Quantification of colonies 
formed in methylcellulose by A673 cells infected with a control shRNA (Luc) or a 
KRT17 shRNA and re-expressing an empty vector, KRT17 cDNA or a constitutively 
active (myristoylated) form of AKT. Error bars indicate SD of duplicate assays. P-values 
were determined using a student’s t-test comparing all conditions to the control 
knockdown/empty vector condition (*** for p≤0.001). (C) Quantification of colonies 
formed in methylcellulose by A673 cells treated with a selective AKT inhibitor or a 
vehicle control for 24 hours. Error bars indicate SD of duplicate assays. (D) Western blot 
analysis of A673 cells described in (C). Protein lysates from treated cells and from 3D 
colonies at the end of the anchorage-independent colony forming assay, were probed with 
phosphorylated-AKT (S473) and total AKT antibodies. Tubulin was used as the loading 
control. The total amount of protein obtained from the 3D colonies was much less that 
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Supplementary Figure S6.1 Validation of EWS and REST coregulated genes. (A) 
Short-hairpin RNA (shRNA) mediated knockdown of EWS or REST in TC71 cells 
results in increased expression of tested neuronal genes. (B) Transient knockdown of 
EWS or REST by siRNA. (C) The expression of indicated neuronal genes were increased 































































































































Supplementary Figure S6.2 Functional analysis of EWS and REST. (A) Growth curves 
of A673 cells with control or EWS or REST knockdown. (B) Anchorage-independent 
growth analyses of A673 cells with control or EWS or REST knockdown. (C) Tissue 
culture growth of TC71 cells with reduced control or EWS or REST level. D, Soft agar 
analyses of TC71 cells with reduced control or EWS or REST level. E, TC71 cells with 
enforced expression of EWS isoforms or REST grow similarly in tissue culture. F, 
Increased expression of EWS V2 or V3 or REST but not EWS V6 in TC71 cells decrease 










3 6 9 12 15
























































































































































































MECHANISM AND RELEVANCE OF EWS/FLI-MEDIATED 

















This work is reprinted with the permission of Oncogene. The manuscript was originally 



















































Supplementary Figure S7.1 Validation of EWS/FLI direct downregulated genes. (A) 
qRT-PCR validation of the EWS/FLI downregulated gene expression signature in A673 
cells following knockdown of endogenous EWS/FLI with the EF-2-RNAi retroviral 
construct. Error bars indicate standard deviation (SD). GAPDH is shown as a control 
gene unaffected by the knock-down. (B) qRT-PCR validation of EWS/FLI mediated 
repression of TGFBR2 in A673, TC71 and TC32 Ewing sarcoma cells following 
knockdown of endogenous EWS/FLI (with EF-2-RNAi) and rescue with an EWS/FLI 
cDNA construct that is resistant to the RNAi effect.  Luc-RNAi is a negative control. 
Error bars indicate SD. (C) ChIP of EWS/FLI at the TGFBR2 promoter in A673 cells 
using antibodies against FLI (which recognizes EWS/FLI) or ELK1 (negative control). 
Data are plotted as fold enrichment compared to the average enrichment of two negative 
control genes. The error bars indicate standard error of means of five independent 
experiments. We were unable to demonstrate loss of binding following knock-down of 
EWS/FLI, and restoration of binding following re-expression likely due to the efficacy of 
the RNAi effect.  Even with ~80% EWS/FLI knockdown in RNA and protein expression 
the remaining 20% of protein likely still binds to relevant target sites, albeit at reduced 
levels overall. While this should be sufficient to observe reduced binding, the level of 
“background” binding to irrelevant sites in the genome is likely reduced by a similar 








Supplementary Figure S7.2 TGFβR2 has tumor suppressive roles in Ewing sarcoma. 
(A) Western blot analysis of A673, TC71, and TC32 cells expressing 3X-FLAG LOX, 
3X-FLAG TGFBR2 cDNA or an empty vector control.  Expressed proteins were detected 
with an anti-FLAG antibody, and anti-Tubulin was used as a loading control. (B) 
Quantification of colonies formed in soft agar by A673, TC71 and TC32 cells expressing 
3X-FLAG TGFBR2 cDNA as compared to cells expressing an empty vector control. 
Error bars indicate SD of duplicate assays. (C) Growth assays (3T5) for A673, TC71 and 
TC32 cells expressing 3X-FLAG TGFBR2 cDNA as compared to cells expressing an 
empty vector control. (D) Tumor volumes were measured using digital calipers and 
plotted for immunocompromised mice subcutaneously injected with TC32 Ewing 
sarcoma cells expressing an empty vector control or 3X-FLAG LOX cDNA. Tumor 
volumes are plotted at two time points, Day 12 and Day 16 postinjection. Five mice were 
used per group, both flanks of each mouse were injected, therefore, 10 total tumors were 
measured. The three TC32 clones with modulation of EWS/FLI used in Fig. 7.1 of the 
primary manuscript could have been a useful tool to address what fraction of EWS/FLI 
tumorigenicity is LOX-mediated. However, given that the survival curves comparing 
empty vector versus LOX cDNA expressing TC32 cells are only separated by a week 
(Fig. 7.2C), this would be a very challenging experiment to interpret. Furthermore, we 
have previously shown that xenograft experiments using EWS/FLI knockdown exhibit an 
“escapee” effect, whereby the RNAi knockdown effect is lost over time (7). Thus, 
comparisons between EWS/FLI knockdown and LOX expression would be confounded 
by this effect as well, making direct comparisons essentially uninterpretable. (E) Survival 
curves for immunodeficient mice injected with TC32 cells expressing 3X-FLAG 
TGFBR2 cDNA or an empty vector construct. The log-rank (Mantel-Cox Test) 
determined p-value using GraphPad Prism is indicated. (F) Western blot analysis of 
tumors excised from immunodeficient mice injected with TC32 cells expressing the 
indicated 3X-FLAG cDNAs. (G) Graphical representation of TGFBR2 expression levels 
in 27 primary Ewing sarcoma patient-derived tumors and ten Ewing sarcoma cell lines in 
the Schaefer et al. dataset. The EWS/FLI or EWS/ERG translocation fusion status for 
each sample is indicated. The Schaefer et al. dataset compared Ewing sarcoma specimens 
to analyze differential gene expression between metastatic and localized tumors.  There 
was no normal tissue used as a baseline reference.  Thus, the LOX and TGFBR2 levels 
were direct expression levels obtained on the Affymetrix microarray platform. However, 
we note that our own microarray datasets of EWS/FLI-mediated transcriptional profiles 
(7, 9, 32) using Affymetrix microarray platforms, each demonstrated low LOX and 
TGFBR2 expression in the presence of EWS/FLI expression, and increased LOX and 
TGFBR2 expression following EWS/FLI knockdown.  Thus, the low absolute expression 
levels observed by Schaefer et al. is well-correlated to our own published microarray 
data, supporting our assertion that primary Ewing sarcoma tumors also exhibit low-level 








(Supplementary Figure S7.2 continued) 
 
150 

















Supplementary Figure S7.3 Expression and DNA-binding of EWS/FLI deletion 
mutants. (A) Western blot analysis of A673 cells infected with an empty vector control 
retrovirus, or retroviruses expressing 3X-FLAG wild-type EWS/FLI, or the Δ22, R2L2 or 
Δ89-C mutants. Tubulin was used as the loading control. (B) Western blot analysis of 
samples from Figure S3.A demonstrating the efficiency of the EWS/FLI RNAi. The 3X-
FLAG tagged mutant constructs that are re-expressed are indicated with a red asterisk, 
while the band position of the endogenous EWS/FLI is indicated. Tubulin was used as 
the loading control. Because some of the EWS/FLI deletion mutants are approximately 
the same size as endogenous EWS/FLI, it can be difficult to evaluate the endogenous 
EWS/FLI band by Western blotting.  Therefore, we have also included the qRT-PCR 
(Figure S7.3C) data for all the EWS/FLI knock-down/rescues to demonstrate efficiency 
and maintenance of the EWS/FLI RNAi effect. (C) Quantitative RT-PCR analysis to 
demonstrate efficiency and maintenance of EWS/FLI knock-down in A673 cells with the 
EF-2-RNAi construct, re-expressing an empty vector, 3X-FLAG tagged EWS/FLI or 
mutant constructs. Luc-RNAi is a negative control. (D) Western blot analysis of A673 
cells infected with empty vector or 3X-FLAG EWS/FLI or the indicated mutants. 
Tubulin was used as the loading control. (E) Western blot analysis of samples from 
Figure S3.D to demonstrate the efficiency of the EWS/FLI RNAi. The 3X-FLAG tagged 
mutant constructs that are re-expressed are indicated with a red asterisk while the band 
position of endogenous EWS/FLI is indicated. Tubulin was used as the loading control. 
(F) EMSA with a DNA duplex (I) containing a high-affinity EWS/FLI-binding site, 
called “ETS2 probe.” A specific EWS/FLI band indicated by a red asterisk is present 
when 3X-FLAG EWS/FLI or 3X-FLAG deletion mutants of EWS/FLI from nuclear 
extracts are included. The specific band in each case is supershifted with the anti-FLAG 
antibody and competed with an excess of unlabeled DNA duplex (I) A control nuclear 
extract that does not contain wild-type EWS/FLI or deletion mutants of EWS/FLI as well 
as the DNA binding mutant (R2L2) nuclear extract generate only nonspecific binding 






























Supplementary Figure S7.4 Expression of EWS/FLI mutant constructs. (A) Western 
blot analysis of A673 cells infected with the indicated RNAi constructs and rescued with 
an empty vector or the indicated constructs. Protein expression was detected with an anti-
FLI antibody, and the positions of endogenous EWS/FLI, Δ22, and 2xVP16/FLI are 
indicated.  Note that re-expressed EWS/FLI is 3xFLAG tagged, and thus runs slightly 
slower than endogenous EWS/FLI.  NS indicates nonspecific bands. Tubulin was used as 
the loading control. (B) Western blot analysis of A673 cells infected with the indicated 
constructs used for the in vivo xenograft tumor formation assay. Protein expression was 
detected with an anti-FLI antibody, and the positions of endogenous EWS/FLI, Δ22, and 
2xVP16/FLI are indicated (with 3xFLAG EWS/FLI running slightly slower than 




















Supplementary Figure S7.5 Validation of the role of HDACs in EWS/FLI-mediated 
target gene repression. (A) qRT-PCR analysis of LOX and TGFBR2 expression following 
retroviral knockdown of NKX2.2 or NR0B1 transcripts in A673 cells. Error bars indicate 
SD. Western blots indicate levels of NKX2.2 and NR0B1 knock-down in A673 cells. 
Tubulin was used as the loading control. (B) qRT-PCR analysis of LOX and TGFBR2 
expression following treatment of HEK293 cells with increasing doses of the HDAC 
inhibitor vorinostat. (C) qRT-PCR analysis of LOX and TGFBR2 expression following 
siRNA-mediated knock-down of HDAC1, HDAC2 or HDAC3 in A673 cells compared to 
a control siRNA knock-down. Knock-down of HDAC1 and HDAC2 results in a 
significant increase in expression of LOX and TGFBR2 indicated by the p-values, n.s. 
indicates nonsignificant p-value. (D) Western blot analysis of HDAC1, HDAC2 and 
HDAC3 levels in A673 cells following siRNA-mediated knock-down compared to a 
























Supplementary Figure S7.6 Identifying corepressors involved in EWS/FLI-mediated 
gene repression; validating the role of LSD1 in transcriptional repression by EWS/FLI. 
(A-C) qRT-PCR of the indicated transcripts following knockdown of the Sin3A repressor 
complex, the REST repressor complex or the NCoR/SMRT repressor complex, 
respectively. Error bars indicate SD. Inset panels show Western blot analysis to 
demonstrate significant knock-down of the Sin3A, REST and NcoR/SMRT repressor 
complexes in A673 cells. Wild-type EWS protein and Tubulin were used as loading 
controls for the Western blot analysis. (D) Relative cell viability assay of A673 cells 
treated with the indicated concentrations of the LSD1 inhibitor HCI-2528. IC50 (as 
determined by GraphPad Prism) was 0.47μM. Error bars indicate SD. (E) qRT-PCR 
analysis of LOX and TGFBR2 mRNA expression in A673 cells after 72 hours of 
treatment with the indicated concentrations of the LSD1 inhibitor HCI-2528. The dose 
corresponding to the IC50 is indicated. Error bars indicate SD. (F-H) Cell viability assays 
performed on TC71, TC32 and SK-N-MC cell lines treated with the indicated 
concentrations of LSD1 inhibitors HCI-2509 and HCI-2528. The IC50 for each inhibitor 
(as determined by GraphPad Prism) is shown. Error bars indicate SD. (I) qRT-PCR 
analysis of LOX and TGFBR2 expression following 72 hours of treatment of HEK 293 
cells with increasing doses of the LSD1 inhibitor (HCI-2509). Error bars indicate SD. (J) 
qRT-PCR analysis of LOX and TGFBR2 expression at 72 hours following siRNA-
mediated knock-down of LSD1 in A673 cells. Increasing concentrations of the LSD1 
siRNA resulted in a dose dependent increase in expression of LOX and TGFBR2. 
Western blot analysis demonstrating the efficiency of the LSD1 siRNA, although the 
dose dependent decrease in the LSD1 protein expression is less obvious in the scanned 
image (the Western blot film shows a slight dose dependent decrease in the LSD1 protein 
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CONCLUSIONS AND FUTURE DIRECTIONS 
James Ewing first described the pediatric bone and soft tissue associated 
malignancy called Ewing sarcoma in 1921 (1). In the mid-1980s the identification and 
characterization of the reciprocal translocation, t(11;22)(q24;q12), in the majority of 
Ewing sarcoma tumors was the first big step in determining the molecular genetics 
underlying the disease (2). The chromosomal rearrangement was found to encode the 
fusion protein EWS/FLI, which functions as an aberrant oncogenic transcription factor 
(3, 4). Since then, several other EWS/ETS and TET/ETS based fusion proteins have been 
identified in Ewing sarcoma. Hence, Ewing sarcoma is predominantly a TET/ETS driven 
malignancy (5).  
The Ewing sarcoma genome is relatively stable. Indeed, very few if any 
secondary mutations have been identified in Ewing sarcoma (6, 7). In addition, few copy 
number gains and losses have been reported in this disease (8), further highlighting that 
the EWS/FLI fusion (and other TET/ETS fusions) is the main gain-of-function mutation 
in Ewing sarcoma, and that transcriptional changes mediated by EWS/FLI are critical 
effectors of the disease process. The lack of secondary genetic changes, such as 
activating mutations in the PI3K, RAS pathways etc., or inactivating mutations in known 
tumor suppressors like RB etc., further highlight the central role of EWS/FLI, the
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initiating oncogenic event, in Ewing sarcoma. Therefore, the working model is that 
EWS/FLI (and other TET/ETS fusions) is the major driver of Ewing sarcoma 
development, and it does so by functioning as a central mediator of a hierarchy of 
transcriptional networks, by activating and repressing critical target genes in Ewing 
sarcoma. The EWS/FLI target genes then contribute to various aspects of oncogenic 
transformation and maintenance, including anchorage-independent growth [e.g., NKX2.2 
(9), NR0B1 (10), GLI1 (11), LOX (12)], selfsufficiency of growth signals [e.g., IGF1 
(13)], insensitivity to antigrowth signals [e.g., TGFBR2 (12, 14)], resistance to 
chemotherapy [e.g., GSTM4 (15)], tissue invasion and metastasis [e.g., EZH2 (16)], 
evasion of apoptosis [e.g., IGFBP3 (17)], limitless replicative potential [e.g., hTERT 
(18)], sustained angiogenesis [e.g., VEGF (19)], thus, bypassing the need for 
accumulating secondary mutations to drive oncogenesis (20). This model is further 
supported by the fact that ongoing EWS/FLI protein expression is required for the 
transformed phenotype of Ewing sarcoma cells (9, 10, 21).  
Much effort has been focused on deciphering the molecular targets of EWS/FLI 
and determining how these critical target genes contribute to the pathogenesis of Ewing 
sarcoma (22). However, the big unanswered question in the field was, mechanistically, 
how does the transcription factor EWS/FLI regulate its target genes? Furthermore, what 
are the EWS/FLI binding elements at target gene promoters? Also, how does the same 
fusion oncoprotein activate and repress target genes in Ewing sarcoma? The goal of this 
thesis was to understand the mechanisms by which EWS/FLI directly upregulates and 
downregulates critical target genes in Ewing sarcoma. It is hoped that an enhanced 
understanding of the mechanisms utilized by EWS/FLI to dysregulate gene expression, 
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and insight as to the proteins it interacts with to achieve this function, will lead to the 
development of new and effective targeted therapies. 
 
DNA binding by EWS/FLI 
In the process of identifying direct EWS/FLI target genes in Ewing sarcoma we 
identified microsatellite repeats as novel EWS/FLI response elements (23). As detailed in 
Chapters 3 and 4, combining genome wide localization of EWS/FLI with transcription 
profiling data we determined that the mechanism of regulation of a subset of EWS/FLI 
target genes, including critical targets like NR0B1 and GSTM4 that are absolutely 
necessary for oncogenic transformation, is through GGAA-microsatellite repeats (15, 23). 
The identification of GGAA-microsatellites as EWS/FLI response elements was 
surprising given that these repeats were previously considered “genomic junk” with no 
biological function (24). These studies have since been independently validated by 
several research groups using more recent ChIP-sequencing techniques (25, 26). 
Interestingly, the NR0B1 GGAA-microsatellite response element has recently been used 
as a tool to screen for drugs that inhibit EWS/FLI activity (27), further highlighting the 
wide-ranging applicability and significance of this research.  
Among the EWS/FLI direct targets, only about 10% harbor GGAA microsatellites 
as the EWS/FLI response element (23). Of the remaining 90% of direct targets, a small 
but significant proportion harbors the high-affinity ETS consensus site as the EWS/FLI 
response element. Bioinformatics analysis revealed that both the microsatellites and the 
high-affinity ETS sites were only enriched in the promoters of EWS/FLI direct 
“activated” target genes. Using ChIP-sequencing approach, a recent study identified 
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frequent occurrences of combinations of two ETS binding sites in several EWS/FLI 
direct-activated target genes (25). This data raises the possibility that EWS/FLI may 
activate transcription from some promoters as a homo- or heterodimer with other ETS 
transcription factors. In addition to microsatellites and high affinity ETS sites, composite 
sites for transcription factors including, E2F, NRF1 and NFY with ETS sites are also 
overrepresented in a subset of EWS-FLI direct activated targets (28), suggesting that 
cooperative interactions may occur between EWS-FLI and specific cognate transcription 
factors to regulate transcription from a subset of these promoters.  
Interestingly, EWS/FLI direct “repressed” target genes lack both the GGAA 
microsatellites and the high-affinity ETS consensus sites. Therefore, EWS/FLI binding to 
GGAA microsatellites or the high-affinity ETS sites is associated solely with gene 
activation. Early inspection of the promoter regions of direct-repressed EWS/FLI targets 
both by ChIP-Chip (Sankar, unpublished observation) and later by ChIP-sequencing (26) 
revealed an enrichment of ETS/AP1 composite binding sites. EWS/FLI (and other 
EWS/ETS proteins) has previously been shown to interact with AP1 proteins (29). 
Additionally, this cooperative interaction was shown to be necessary for transformation 
by the EWS/ETS fusion proteins. These data suggest that ETS/AP1 motifs may act as 
functional sites for EWS/FLI binding at promoters of repressed genes. However, 
additional work is required to identify and characterize EWS/FLI binding motifs at direct 
repressed target genes. Also, future studies focused on more detailed analysis of the 
EWS/FLI binding sites at target gene promoters and enhancers, identified by increasing 
the number of sequencing reads for EWS/FLI in a ChIP-sequencing based approach, may 
reveal other new binding motifs for the fusion protein in the Ewing sarcoma genome. 
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Transcriptional activity of EWS/FLI 
An important question raised by these studies is: what are the key determinants of 
transcriptional outcome following EWS/FLI binding? How does EWS/FLI decide 
between transcriptional activation versus transcriptional repression? Several models can 
explain this functional dichotomy in the EWS/FLI fusion protein and these models are 
not mutually exclusive. As alluded to previously, one model involves “the binding motif” 
and the “local protein concentration”; the presence of GGAA-microsatellite repeats or the 
consensus high-affinity ETS site at promoters of upregulated genes may allow for 
EWS/FLI binding and subsequent recruitment of coactivator proteins, to achieve higher 
local concentration at these sites, leading to gene activation. Conversely, the absence of 
these motifs may allow for EWS/FLI binding at variant low-affinity sites, subsequent 
recruitment of corepressor proteins, which may be abundant at these sites, leading to gene 
repression.  
A second model which highlights a key determinant of transcriptional outcome is 
the “chromatin architecture and the histone modifications” present at target gene 
promoters. EWS/FLI bound GGAA-microsatellite repeat regions are nucleosome 
depleted, RNA polymerase II bound and harbor the chromatin signature of enhancer 
elements characterized by the enrichment of histone H3 lysine 4 mono- and di-
methylation (H3K4me1/2) (26). Interestingly, silencing of EWS/FLI in Ewing sarcoma 
cells leads to increased nucleosome occupancy at the GGAA repeat elements and, 
conversely, ectopic expression of EWS/FLI in non-Ewing sarcoma cells like primary 
endothelial cells leads to nucleosome depletion at a subset of GGAA-microsatellite 
regions that are normally associated with repressive chromatin (26). These data suggest 
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that the EWS/FLI fusion protein acquires chromatin-altering activity, leading to 
chromatin disruption and ultimately, transcriptional dysregulation. Furthermore, despite 
their identical DNA-binding domains, the tumor-specific genomic retargeting of the 
EWS/FLI fusion protein is achieved in comparison to the parental transcription factor, 
FLI1 in Ewing sarcoma cells (26). These data suggest that EWS/FLI may function as a 
“pioneer factor” capable of inducing and maintaining either open or closed chromatin 
architecture by virtue of its interactions with chromatin remodeling proteins.  
In the process of identifying direct-repressed targets of EWS/FLI, and 
understanding the mechanism of EWS/FLI-mediated transcriptional repression, we 
identified that EWS/FLI interacts with the NuRD (nucleosome remodeling and histone 
deacetylase) chromatin remodeling complex to directly repress a subset of critical target 
genes in Ewing sarcoma (refer to Chapter 7) (12). NuRD is a repressor complex, but 
interestingly, a recent study demonstrated that some of the NuRD complex members may 
be recycled into an activating complex called the NuRF complex (nucleosome 
remodeling factor) (30), thereby allowing for a “switch” between transcriptional 
activation and repression.  
These new findings raise the possibility of a third “dynamic switch” model, 
whereby, in Ewing sarcoma a switch between the NuRD and NuRF complexes may exist. 
The NuRD complex may function as the “epigenetic reader” of chromatin modifications 
at target gene promoters, and through a coordinated effect of the local epigenetic 
architecture, and the DNA motif EWS/FLI is bound to, the NuRD complex may be 
stabilized to cause transcriptional repression or may be destabilized, allowing EWS/FLI 
to then interact with the NuRF complex leading to transcriptional activation. The same 
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domains within EWS/FLI may be able to interact either with the NuRF (activator) or 
NuRD (repressor) complexes in Ewing sarcoma cells making these two functions 
inseparable on the EWS/FLI molecule and, suggesting that competition may occur for 
cofactor interaction with EWS/FLI. In support of this are data presented in Chapter 7 
(12), demonstrating our inability to separate activation and repression functions, using 
deletion mapping analysis, on the EWS/FLI molecule. These data suggest that the same 
domains within the protein may interact with coactivators or corepressor proteins, 
depending on the promoter context. Importantly, both activation and repression by 
EWS/FLI are necessary for full oncogenic transformation in Ewing sarcoma (12). 
Collectively, the work outlined in this dissertation is a step toward understanding 
the mechanisms of EWS/FLI mediated transcriptional regulation of target genes, and 
opens up several interesting questions as potential future directions. What is the 
epigenetic landscape of Ewing sarcoma cells and how does EWS/FLI affect the histone 
modifications and the chromatin signature at target gene promoters and enhancers? Since 
EWS/FLI has the ability to modulate nucleosome occupancy, which chromatin remodeler 
proteins does it interact with in Ewing sarcoma? Is the NuRD complex the predominant 
remodeler and repressor complex recruited by EWS/FLI? Is there a switch between the 
NuRD and the NuRF complexes that determine the transcriptional fate of the EWS/FLI 
bound target genes? LSD1 is part of the NuRD complex, and LSD1 has both 
transcriptional activation and repressive functions. Since LSD1 activity is important in 
Ewing sarcoma (Chapter 7), the next important question in this direction is: does LSD1 
play a more central role in EWS/FLI-mediated transcription; does it affect EWS/FLI-
mediated activation and repression? What fraction of EWS/FLI targets is affected by 
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modulating LSD1 activity in Ewing sarcoma? Apart from the NuRD complex, 
identification of a functional interaction between the REST corepressor complex and 
EWS (refer to Chapter 6), also raises the possibility that EWS/FLI, by virtue of the N-
terminal EWS domain, may also recruit the REST complex to repress a subset of its 
target genes in Ewing sarcoma. 
The overarching goal in our lab is to identify new and more effective treatments 
for Ewing sarcoma patients through detailed molecular studies. Previous efforts in the lab 
were focused on understanding the function of individual target genes of EWS/FLI as a 
step towards this goal (9, 10). However, given that EWS/FLI dysregulates thousands of 
genes in Ewing sarcoma, blockade of EWS/FLI activity itself would be a more ideal 
approach for the treatment of Ewing sarcoma. In contrast to diseases like Chronic 
Myelogenous Leukemia (CML), where Gleevac was developed to target a single kinase 
dependent signaling pathway, the absence of a single aberrant signaling pathway driving 
Ewing sarcoma pathogenesis precludes the development of a “Gleevac-like” drug for this 
disease.  
Therefore, taking a step back and understanding the mechanisms of gene 
regulation by EWS/FLI is necessary to develop new and effective targeted therapy for 
Ewing sarcoma. Based on my dissertation work, we have identified that EWS/FLI utilizes 
HDAC and LSD1 activities for repression of critical tumor suppressor genes. HDAC 
inhibitors are FDA approved for several cancers and offer promise for the treatment of 
Ewing sarcoma. Furthermore, LSD1 is a viable therapeutic target. We have demonstrated 
that two selective and targeted LSD1 inhibitors, HCI-2509 and HCI-2528, not only 
reverse the expression of candidate tumor suppressor genes but also lead to cell death of 
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multiple patient-derived Ewing sarcoma cell lines (12). These studies highlight that LSD1 
inhibitors also have the potential to be developed as effective therapeutic agents for 
patients afflicted with Ewing sarcoma. A clinically effective therapeutic strategy may 
necessitate administration of the HDAC and/or LSD1 inhibitors as a combination therapy 
with currently used chemotherapeutic agents for effective treatment of Ewing sarcoma.  
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